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Diabetes mellitus (DM) is a metabolic disorder which is characterised by hyperglycaemia 
resulting from defects in insulin secretion, insulin action or both. The long-term specific 
effects of DM include the development of retinopathy, nephropathy and neuropathy. Cardiac 
disease, peripheral arterial and cerebrovascular disease are also known to be linked with DM. 
 
Type 1 diabetes mellitus (T1DM) accounts for approximately 10% of all individuals with DM, 
and insulin therapy is the only available treatment. Type 2 diabetes mellitus (T2DM) accounts 
for 90% of all individuals with DM. Diet, exercise, oral hypoglycaemic agents and occasionally 
exogenous insulin are used to manage T2DM. The diagnosis of DM is made where the glycated 
haemoglobin (HbA1c) percentage is greater than 6.5%. 
 
Pattern-reversal visual evoked potential (PVEP) testing is an objective means of evaluating 
impulse conduction along the central nervous pathways. Increased peak time of the visual 
P100 waveform is an expression of structural damage at the level of myelinated optic nerve 
fibres. 
 
This was an observational cross sectional study. The participants were grouped into two 
phases. Phase 1, the control group, consisted of 30 healthy non-diabetic participants. Phase 
2 comprised of 104 diabetic participants of whom 52 had an HbA1c greater than 10% (poorly 
controlled DM) and 52 whose HbA1c was 10% and less (moderately controlled DM). 
 
The aim of this study was to firstly observe the possible association between glycated 
haemoglobin levels and P100 peak time of pattern-reversal visual evoked potentials (PVEPs) 
in DM. Secondly, to assess whether the central nervous system (CNS) and in particular visual 
function is affected by type and/or duration of DM. 
 
The cut-off values to define P100 peak time delay was calculated as the mean P100 peak time 
plus 2.5 X standard deviations as measured for the non-diabetic control group, and were 
110.64 ms for the right eye. 
 
The proportion of delayed P100 peak time amounted to 38.5% for both diabetic groups, thus 
the poorly controlled group (HbA1c > 10%) did not pose an increased risk for delayed P100 
peak time, relative to the moderately controlled group (HbA1c ≤ 10%). The P100 PVEP results 
for this study, do however, reflect significant delay (p < 0.001) of the DM group as compared 
to the non-diabetic group; thus, subclincal neuropathy of the CNS occurs in 38.5% of cases. 
The duration of DM and type of DM had no influence on the P100 peak time measurements. 
 
Keywords: Diabetes mellitus, glycated haemoglobin percentage, visual evoked potential. 
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Chapter 1 
Introduction 
 
1.1 Definition of diabetes mellitus (DM) 
 
The World Health Organization (WHO, 1999) describes the term diabetes mellitus (DM) as 
referring to a ‘metabolic disorder with heterogeneous aetiologies which is characterised by 
chronic hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both’.  
 
1.2 Effects of DM 
 
The long-term pathological effects of DM include the development of retinopathy, 
nephropathy and neuropathy. Individuals with diabetes are also predisposed to other 
diseases including cardiac, peripheral arterial and cerebrovascular diseases (Alberti & 
Zimmet, 1998).  
 
The International Diabetes Foundation (IDF) estimated that 387 million people worldwide 
were living with diabetes in 2014 with the majority (80%) of these residing in low- and middle-
income countries (IDF, 2014). The IDF projects this number will increase to 592 million by the 
year 2035. 
 
1.3 Classification of DM 
 
The two most common forms of diabetes are Type 1 diabetes mellitus (T1DM) ‒previously 
described as insulin-dependent (IDDM) ‒and Type 2 diabetes mellitus (T2DM) ‒previously 
described as non-insulin dependent diabetes (NIDDM). Both Type 1 and Type 2 DM are caused 
by a combination of environmental and genetic factors that are briefly discussed next. 
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1.4 Epidemiology of Type 1 diabetes mellitus (T1DM) 
 
Type 1 DM accounts for approximately 10% of all individuals with diabetes (Rewers, 1991). It 
is caused by the autoimmune destruction of the beta cells in the pancreas. Life-long 
exogenous insulin therapy administered in injection form is at present the only treatment 
available; without this treatment a person with T1DM will have a reduced healthy life 
expectancy (Imagawa et al., 2000). According to Holt (2004), an estimated 20 million people 
worldwide, mainly children and young adults, have T1DM. According to Holt (2004), asthma 
is the only chronic childhood disorder more prevalent than T1DM.  
 
There is an increase of 2-5% per annum in the worldwide incidence rate of T1DM (Maahs et 
al., 2010). Epidemiologic studies have shown there is not a big difference in the incidence 
among individuals of different genders diagnosed before the age of 15 (Kyvik et al., 2004). 
The male-to-female incidence ratio is approximately 1.5 after the age of 25 years (Dorman & 
Bunker, 2000).  
 
1.5 Environmental risk factors associated with Type 1 diabetes mellitus (T1DM) 
 
Environmental risk factors are considered to be initiators or accelerators of beta cell 
autoimmunity. The most prevalent T1DM environmental risk factors are viruses and infant 
nutrition (Martin et al., 1991). Common viruses during childhood are the enteroviruses, 
including the Coxsackie viruses and polioviruses that have systemic effects on the pancreas 
(Dahlquist, 1998). Other viruses that have been linked with T1DM include the 
cytomegalovirus (CMV) (Pak et al., 1988), rubella (Menser & McIntosh, 1992), mumps (Hyoty 
et al., 1995) and the rotavirus (Honeyman et al., 2000). 
 
Early exposure to the protein in cow’s milk has been linked with T1DM as observed by Borch-
Johnsen et al. (1984). These authors found that children with T1DM had been breastfed for a 
shorter time than their non-diabetic siblings or the non-diabetic children from the general 
population. It was therefore postulated by these authors that a shorter time of breastfeeding 
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may trigger incipient exposure to dietary proteins that induce an abnormal immune response 
in infants. 
 
Delayed exposure to microorganisms due to higher standards of living may compromise the 
development of the immune system, and thus the role of hygiene has been hypothesised in 
the aetiology of T1DM (McKinney et al., 1997). 
 
1.6 Epidemiology of Type 2 diabetes mellitus (T2DM) 
 
Type 2 DM is the most prevalent form of the disease afflicting 90% of all individuals with 
diabetes. It is caused by altered insulin secretion and peripheral insulin resistance. Diet, 
exercise, oral hypoglycaemic agents and, occasionally, exogenous insulin is used to manage 
T2DM (Alberti & Zimmet, 1998). 
 
According to the results of a study done by Wild et al. (2004) on the global prevalence of DM, 
the vast majority of T2DM are men and woman aged 45 to 64 years who live in developing 
countries. In 2000 it was approximated that 171 million people (2.8% of the world’s populace) 
had DM and by 2030 this figure will more than double to 366 million (4.4% of the world’s 
populace).  
 
These figures were however drastically underestimated as reported by the IDF in their 2013 
report, whereby 382 million people worldwide (8.3% of adult population) were reported to 
have DM, of which 90% being T2DM. The IDF projects that this figure could rise to 592 million, 
by 2035. The IDF (2013) report, rates China (109 million), India (69 million), USA (29 million), 
Brazil (14 million) and the Russian Federation (12 million) as the top 5 countries with the 
highest prevalence of DM. The UK DM prevalence as reported by the British Diabetic 
Association 2014/15 report, indicate that 4 million people have DM in the UK, this represents 
6% of the UK population.  
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1.7 Environmental risk factors related to Type 2 diabetes mellitus (T2DM) 
 
The main environmental risk factors for T2DM is obesity (body mass index ˃ 30kg/m2) and 
leading an inactive lifestyle (Van Dam, 2003). In recent years the significant global rise in 
obesity has been associated with critical increases in the rates of T2DM (Zimmett et al., 2001). 
An estimated 80% of all new T2DM cases in adults and children are as a result of obesity (Lean, 
2000). 
 
A lack of regular physical exercise is a major risk factor for developing T2DM. Exercising not 
only helps to control a person’s weight, but also helps to regulate the glucose and lipid 
metabolisms in the body thereby reducing the risk of T2DM. Making lifestyle changes that 
focus on a healthy diet and exercise reduce the risk of progression from impaired glucose 
tolerance (IGT) to T2DM by 60% whereas oral hypoglycaemic medication only reduces the risk 
of progression from IGT to T2DM by 30% (Pan et al., 1997). 
 
1.8 Role of genetics in the development of DM 
 
First-degree relatives have a greater chance (6%) of developing T1DM than unrelated 
members (1%) of the general population (Dorman & Bunker, 2000). First-degree relatives of 
T2DM are three times more likely to have the disease than those with no positive family 
history of T2DM (Flores et al., 2003; Hansen, 2003).  
 
1.9 Glycated haemoglobin test (HbA1c) for the diagnosis for DM 
 
The glycated haemoglobin test (HbA1c) that indicates the mean plasma glucose over the 
previous eight to 12 weeks (Nathan et al., 2007) has been in clinical use since the 1980s and 
has subsequently become a mainstay of clinical practice (Massi-Benedetti, 2006). A major 
advantage of the HbA1c test is that it can be taken at any time of the day and does not need 
to be taken while fasting. 
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The HbA1c test was recommended in 2009 by an International Expert Committee that 
included members of the European Association for the Study of Diabetes as the foremost 
diagnostic test to be used for the diagnosis diabetes (International Expert Committee, 2009). 
It was recommended by the Association that the HbA1c measurement should not only be 
used to diagnose DM, but also to identify those at risk of progression towards the disease. In 
2011 it was recommended by the WHO that DM be diagnosed with HbA1c ˃ 48 mmol/mol (˃ 
6.5%) (WHO, 2011).  
 
Glycation is the non-enzymic covalent chemical sourcing of glucose onto proteins through 
amino groups. The glycation of proteins occurs in tissues that are exposed to glucose. The 
magnitude of protein glycation is reliant on the level of exposure to glucose. The range of 
glycation is represented as a percentage of total haemoglobin (HbA) (Brownlee, 1994).   
 
The HbA1c percentage depends on the average age of the erythrocytes in the blood specimen 
at the time of measurement; the percentage of HbA1c is higher in older cells (Bunn et al., 
1978). The average red cell lifespan is 117 days in non-diabetics; females have a gender 
difference of around 11 days less (Diem & Lentner, 1970). The concentration of glucose in the 
blood can be changed by food intake, protracted fasting or exercise (Young et al., 2006). Most 
factors that influence fasting plasma glucose (FPG) do not alter HbA1c concentrations. Short-
term lifestyle changes such as exercise and/or food intake has no influence on the HbA1c 
values (Bry et al., 2001).   
 
Hyperglycaemia is the biochemical trademark of DM; however, the fasting and 2-hourly oral 
glucose tolerance test (OGTT) measures only a brief period in a single day. Cardiovascular 
disease (CVD) is the most common chronic complication of DM with a 5- to 10-times higher 
incidence rate compared to that of microvascular disease. Fasting plasma glucose is a poor 
indicator of future CVD events whereas HbA1c are good predictors; this further confirms the 
usefulness of HbA1c in diagnosing DM (Khaw et al., 2004). 
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HbA1c values of ˃ 6.5% confirm the diagnosis of DM. If values are between 6.00 - 6.49% it 
indicates a high risk for DM and an effective prevention plan should be implemented. 
Individuals whose HbA1c values measure 5.50 - 5.99% and who also present with other 
diabetes risk factors such as central obesity, atherogenic dyslipidaemia, hypertension and 
metabolic syndrome should be made aware of their very high risk of developing DM (Bonora 
& Tuomilehto, 2011).  
 
A diagnosis of diabetes is made when the HbA1c is greater than 6.5% (WHO, 2011). Higher 
amounts of glycated haemoglobin indicates poor control of blood glucose levels and this is 
associated with nephropathy, neuropathy and retinopathy (Hanssen et al., 1992). The 
reference range of HbA1c for healthy non-diabetics is 4 - 5.9%. A diabetic person with good 
glucose control has an HbA1c level that is close to the 4 - 5.9% reference range (Koenig et al., 
1976). 
 
1.10 Diabetic neuropathies 
 
Diabetic neuropathy is a well-known complication of DM (Dyck et al., 1993). It may be diffuse 
(involving several body parts) or localised (involving a specific nerve and part of the body). 
 
The nervous system consists of two major divisions: the central nervous system (CNS) that is 
made up of the brain, the cranial nerves, and the spinal cord. Secondly, the peripheral nervous 
system (PNS) comprises the nerves (that join the CNS with the sensory organs), the muscles, 
blood vessels, and glands of the body. The peripheral nerves can be motor, denoting that they 
are involved in motor activity such as walking, or they can be sensory which means they relay 
information back to the CNS. The CNS and the PNS combine to govern autonomic processes 
such as breathing, heartbeat, blood pressure, and visual function. 
 
The neuropathies that ensue in DM are considered to be heterogeneous by their symptoms, 
the pattern of neurologic involvement, the course and pathologic alterations as well as the 
underlying mechanisms (Dyck et al., 1993; Llewelyn et al., 2005). 
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Peripheral diabetic neuropathy  
 
Peripheral diabetic neuropathy, also known as ‘distal symmetric neuropathy’ or 
‘sensorimotor neuropathy’, is a multifactorial condition involving metabolic changes (Greene 
et al., 1987), neurovascular dysfunction (Cameron & Cotter, 1994), and changes in trophic 
support (Brewster et al., 1994). Nerve damage occurs in the arms and legs; the feet and legs 
are generally affected before the hands and arms. Peripheral neuropathy can lead to muscle 
weakness and the loss of reflexes. A common complication is foot infections; if not treated 
quickly the foot infection may spread to the bone which often leads to the need for an 
amputation of the limb (Potter et al., 1998). 
 
Diabetic autonomic neuropathy (DAN) 
 
The condition known as ‘diabetic autonomic neuropathy’ (DAN) is not well understood in 
spite of the considerable negative influence it has on the quality of life and survival (Vinik & 
Erbas, 2001). Often classified as either clinically evident or subclinical, DAN can affect the 
entire autonomic nervous system (ANS). Diabetic autonomic neuropathy is evidenced by the 
dysfunction of one or more organ systems, for example, the cardiovascular, gastrointestinal, 
genitourinary, sudomotor or ocular systems (American Diabetes Association and American 
Academy of Neurology, 1988). However, of more significance is that DAN mostly occurs as a 
widespread disorder affecting all parts of the ANS because many organs are dually innervated 
by receiving fibres of the parasympathetic and the sympathetic divisions of the ANS (Ziegler, 
1999).   
 
Clinical symptoms of DAN do not usually occur for some time after the development of 
diabetes. Subclinical autonomic dysfunction in T2DM can occur within a year of diagnosis and 
within two years after diagnosis of T1DM (Pfeifer et al., 1984). 
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Focal neuropathy 
 
Also described as ‘cranial neuropathy’, focal neuropathy is very rare – especially in individuals 
younger than 50 years. Its onset is thought to occur due to a microvascular ‘infarct’. Such an 
episode can be painless or may be accompanied by a headache. The oculomotor nerve (CN 
III) is most frequently affected but pupil involvement is generally spared. The trochlear (CN 
IV) and the abducens nerves (CN VI) may also be affected (Asbury 1987; Thomas & Tomlinson, 
1993). 
 
Focal neuropathies are limited to the arrangement of single nerves and their inclusion is 
referred to as ‘mononeuropathy’ or ‘mononeuritis multiplex’. Mononeuropathies are due to 
vasculitis and the ensuing ischaemia of the nerves (Vinik et al., 1992). 
 
1.11 Central nervous system (CNS) involvement in DM 
 
The central nervous system (CNS) is structurally and functionally linked to the peripheral 
nervous system (PNS). The CNS is afflicted by the metabolic and vascular ramifications of DM 
(Mijnhout et al., 2006). It has long been accepted that DM can lead to cognitive dysfunction 
(Miles & Root, 1922).  
 
Cognitive dysfunction in DM has a prevalence of roughly 40% in long-standing or poorly 
controlled diabetes (Dejgaard et al., 2005). Hypoglycaemia and not hyperglycaemia has been 
associated with cognitive decline in insulin-treated diabetics (Deary & Frier, 1996). Cognitive 
dysfunction in DM has also been termed ‘functional cerebral impairment’, ‘central 
neuropathy’ and ‘diabetic encephalopathy’ (Mijnhout et al., 2006). 
 
It has been shown that both cognitive dysfunction and peripheral neuropathy are present in 
individual persons with T1DM (Ryan et al., 1993). However, T2DM does not share the same 
mechanisms and risk factors. With regard to peripheral complications, hyperglycaemia is the 
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main protagonist while cerebral complications find their aetiologies more with a vascular 
component than with hyperglycaemia (Sheetz & King, 2002). 
 
The pathological development in the CNS of individuals with diabetes is usually subtle 
whereas vascular trauma results in haemorrhage and infarction of the neuronal tissue. 
Compared to the blood-retinal barrier, the blood-brain barrier is less affected by uncontrolled 
hyperglycaemia. This may be due to the influence of the surrounding tissue and the richness 
of the cerebral microvessels in antioxidant enzymes (Tayaran et al., 1987) that help to protect 
the CNS from metabolic changes caused by hyperglycaemia (Mooradian & Morin, 1991). 
Compelling structural, haemodynamic, biochemical and physiological alterations occur in the 
cerebral microvessels of diabetics. It is these alternations that most likely lead to diabetes-
related complications of the CNS (Mooradian, 1997). 
 
1.12 Definition of visual evoked potential (VEP) 
 
Visual evoked potentials (VEP) represents the response of the visual cortex to stimuli 
presented in the visual field. Visual evoked potential test the function of the visual pathway 
from the retina to the occipital cortex. The conduction of the visual pathways from the optic 
nerve, optic chiasm and optic radiations to the occipital cortex is measured. The information 
acquired from taking these measurements can thus give insight into the integrity of the CNS, 
and in particular into its relationship to visual function. The recording of visual evoked 
potentials to study the detail of the electrical activity of the brain has been possible for almost 
50 years (Cobb & Dawson, 1960). 
 
1.13 General description of VEP 
 
Perfoming a VEP is a simple, sensitive and an objective technique for evaluating impulse 
conduction along the central nervous pathways. Increased peak time of the visual P100 
waveform is an expression of structural damage at the level of myelinated optic nerve fibres. 
The visual cortex responds to various visual stimuli and this elicits different types of visual 
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evoked potential.  The three main types of VEP are pattern-reversal (PVEP), pattern 
onset/offset and flash (FVEP). To record the VEP, the cortex needs to be stimulated as strongly 
as possible (Hubel & Wiesel, 1977).  
 
Neurons in the cortex, unlike photoreceptors, are not strongly activated by stimuli that are 
homogenous over space and time. The stimulus has therefore to be structured in either space 
or time or both to produce a strong response. To meet these criteria the most common stimuli 
for VEP are short flashes or the appearance of contrast reversal of a visual pattern. Not all 
retinal positions are equally represented in the primary visual cortex. Visual resolution 
degrades from the fovea to the periphery, as do the density of the retinal ganglion cells. The 
magnification factor represents the size of the cortical representations as a function of 
position in the visual field (Drasdo, 1977). It therefore follows that the representation of the 
central 10 0 radius represents more than half of the overall cortical representation of the 
visual world and this then dominates the VEP (Horton & Hoyt, 1991). A stimulus diameter of 
15 0 will elicit VEP of near maximal amplitude.  
 
The standard clinical test entails the recordings of the pattern-reversal PVEP. The visual 
stimulus is a high contrast black and white checkerboard covering the central 20 – 30 ° of the 
visual field of which the black and white squares sequentially change places. The PVEP is then 
the averaged response to this reversal. The responses are recorded from three electrodes 
covering the occipital region with a mid-frontal electrode as the voltage reference. The signal 
at the midline occipital electrode usually contains a positive component which occurs roughly 
100ms after the pattern-reversal; this is known as the P100. The P100 is preceded by a smaller 
negative component with a peak time of about 75 ms known as the N75 and, finally, another 
negative peak of N2 or N145 which occurs after the P100. The peak time of the P100 at the 
midline electrode is taken as the measure of the retinostriate conduction time (Walsh et al., 
2005). 
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1.14 Factors influencing PVEP 
 
The size of the checks displayed on the checkerboard screen affects the amplitude of the 
waveform and the peak time of the P100. Because the cells of the visual cortex are maximally 
sensitive to movement at the edges, a pattern-shift with a frequency of 2.0 ± 0.2 reversals per 
second is used (Odom et al., 2010). Additionally, pupillary size and gender as well as age all 
affect the PVEP. Visual acuity of up to 6/60 does not alter the response of the PVEP; instead, 
larger checks may be used. Certain drugs such as those used for epilepsy (carbamazepine and 
sodium valproate) prolong PVEP (Yuksel et al., 1995). 
 
 
 
1.15 Optic nerve and central nervous dysfunction 
 
Visual electrophysical studies of neurological disorders such as multiple sclerosis (MS) as well 
as Parkinson’s disease (PD) have given new insights into the pathophysiology of such 
neurological diseases (Halliday et al., 1973). This has significantly improved knowledge of 
previously unknown aspects of the visual system and its organisation (Halliday et al., 1973). 
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Electrophysiological studies of the optic nerve using pattern PVEP tests have shown an 
increase in the peak time of the P100 wave. The P100 wave reflects the bioelectrical function 
of the optic nerve. Peak time increases in the P100 wave is a subclinical feature of optic nerve 
dysfunction and is usually noted without any pathological changes in the general ophthalmic 
examination. The dysfunction of the ganglion cells measured by electrophysiological tests 
precedes the structural changes observed in the ganglion cell layer. According to Pollock et 
al. (1989), this may explain the cause of visual disturbances reported by patients in the early 
stages of Alzheimer’s disease who present with apparently normal eyes. 
 
Visual evoked potential is a means of objectively evaluating the physiology and 
pathophysiology of the human visual system including the visual pathways and the visual 
cortex. It helps to detect abnormalities in patients with visual complaints who do not present 
with visible pathological ophthalmological changes. Such evoked potential abnormalities are 
called ‘silent lesions’. Pattern-reversal stimuli are the most commonly used method to 
generate VEP in a checkerboard or grating pattern (Regan, 1989). 
 
1.16 Overview and research rationale 
 
The purpose of this study was to investigate whether there is a possible association between 
the P100 peak time of pattern-reversal visual evoked potential (PVEP) and the glycated 
haemoglobin percentage (HbA1c) in DM; to establish whether the central nervous system, in 
particular the visual function, is affected resulting in DM-related central neuropathy, and 
whether the type of diabetes and the duration that the participant has been diagnosed as a 
diabetic are relevant. 
 
In DM the most common determinant of visual loss is retinopathy (Ewing et al., 1998). 
According to Karlica et al. (2010), this visual loss is a result of vascular and metabolic 
abnormalities of the retina. These researchers found VEP to be effective in identifying retinal 
dysfunction in that damage to retinal ganglion cells in DM can be detected where normal 
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visual acuity has been attained. Ganglion cell damage can be viewed as preclinical diabetic 
retinopathy where there is no ophthalmoscopic evidence of retinopathy (Karlica et al., 2010). 
Diabetic retinopathy (DR) is characterised as an advancing disease of the retinal vasculature 
(Antonetti et al., 2006). The clinical diagnosis of DR is made where lesions to the retinal 
vasculature are visible by observation means such as ophthalmoscopy or fundus photography 
(Early Treatment Diabetic Retinopathy Study [ETDRS], 1991). The clinical appearance of DR is 
due to an increased vascular permeability, vascular closure, and retinal ischaemia (Antonetti 
et al., 2006). 
 
Visual evoked potential is a non-invasive procedure used to objectively examine the activity 
of the visual system as well as to investigate the integrity of the visual pathway in optic 
neuritis (Hood et al., 2000). Jones and Brusa (2003) suggest the resulting conduction change 
can be qualitatively evaluated by observing the peak time delay of the VEP. In the same study 
Jones and Brusa (2003) found that the original peak time delay of the VEP correlates to the 
size of the demyelinated area of the optic nerve. 
 
The results of this study could impact on healthcare professionals involved in managing DM 
as well as all those individuals who have DM. The integrity of the participants’ CNS will be 
established without the use of expensive and invasive medical procedures. Compared to 
previous studies that only referred briefly to the type of DM, and in which the control or 
duration of DM was not considered, this study will evaluate two distinct groups of 
participants, namely, those with poorly controlled DM (HbA1c > 10%) and those with 
moderately controlled DM (HbA1c ≤ 10%). Participants with other ophthalmic or neurological 
pathologies will be excluded so as to not influence the study results. It is thus by distinction 
of comparing two diabetic groups with no obvious ophthalmic pathology as well as by noting 
the duration the participants had their diabetes controlled that this study aimed to address 
the knowledge gap left open by previous studies. 
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1.17 Summary 
 
This chapter covered brief descriptions of DM. The effects of DM and the involvement of the 
CNS were also mentioned. Visual evoked potential was also briefly described. In the next 
chapter a literature review will be presented. 
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Chapter Two 
Literature Review: the role of visual evoked potential in diabetes mellitus 
 
In the previous chapter the study was introduced. The introduction covered describing DM, 
the effects of DM and the involvement of the CNS. Visual evoked potential (VEP) was also 
described and explained. This chapter presents a more specific literature review on the role 
of the VEP in DM. The literature review was an important aspect of the research since it 
formed the basis of the methodology followed in this study.  
 
2.1 Introduction 
 
An in-depth literature review was conducted to determine the existing knowledge and 
current developments related to the association between glycated haemoglobin levels and 
P100 visual evoked potential (VEP) in diabetes mellitus (DM). The review also considers 
whether the central nervous system (CNS) and in particular visual function is affected by 
diabetes and, if so, the type of diabetes involved. 
 
Relevant articles were identified covering DM and VEPs as well as central neuropathy that 
were published in peer-reviewed journals.  
 
A search of the National Library of Medicine and the Web of Science database was done to 
identify all applicable articles published between 1970 and October 2014. Keywords and 
phrases used for the search to investigate the association between glycated haemoglobin 
levels and P100 visual evoked potential in DM included ‘diabetic neuropathy’; ‘diabetic 
encephalopathy’; ‘visual evoked potential and diabetes’; ‘diabetic central neuropathy and 
VEP’ and ‘glycated haemoglobin levels and vision’. Searches were restricted to ‘humans’.  
 
In total 34 peer reviewed articles were identified. Of these 34 identified articles 28 were 
included in the literature review of this study. Six studies were excluded due to their unrelated 
testing techniques and protocols from the present study. 
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Table 2.1 lists the main studies used in this literature review and these were chosen to be 
included based on each individual study closely corresponding to the literature investigation 
carried out.  
Studies denoted with an asterisk complied with the ISCEV standards for clinical visual evoked 
potentials. 
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Table 2.1 - VEP studies related to DM 
P100 peak time 
delayed in H1A1c > 7 %  
no peak time delay 
significant delay with 
positive correlation to 
duration of DM 
P100 peak time 
correlation with duration 
of DM 
delayed P100 significantly 
delayed HbA1c > 7% 
significant delay in both 
diabetic groups 
significant delay in both 
diabetic groups 
both groups of participants 
P100 have peak time 
delay 
Significantly delayed P100 
of both diabetic groups 
Number of 
Participants 
40 Control 
40 T2DM 
30 Control 
74 NIDD 
20 Control 
20 T1DM 
20 Control 
20 NIDD 
 20 Control 
40 T2DM 
40 Control 
40 T2DM 
30 Control 
90 T2DM 
13 Control 
3 NPDR T2DM 
50 Control 
20 T1DM 20 T2DM 
Diabetic 
Retinopathy 
no retinopathy 
NPDR 
 
noted 
nil 
nil 
nil 
20 no retinopathy 
20 NPDR 
nil 
2 no retinopathy 
3 NPDR 
nil 
Duration 
of DM 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
Control of 
DM 
noted and 
compared 
not noted 
noted 
noted 
noted 
noted 
not noted 
noted 
noted 
Type of 
DM 
T2DM 
NIDD 
T1DM 
NIDD 
T2DM 
T2DM 
T2DM 
T2DM 
T1DM 
and 
T2DM 
Author and Year 
Kumar et al., 2014 
Ismail, 2014 
Shrivastava et al., 2014* 
Bhanu et al., 2012* 
Gayathri et al., 2012* 
Heravian et al., 2012* 
Chopra et al., 2011* 
Wolff et al., 2010 
Al-idani et al., 2009 
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P100 peak time 
delayed P100 
increase of VEP peak time 
significant P100 delay 
significantly delayed P100 
P100 significantly delayed in 
diabetic group 
Significantly delayed P100 of 
both diabetic groups 
increased P100 peak time 
increased P100 in diabetic 
participants 
increased peak time P100 
Number  
of Participants 
40 T1DM 
40 T2DM 
30 Control 
51 T2DM 
30 Control 
30 T1DM 
14 Control 
14 IDDM 
20 Control 
6 IDDM 
21 NIDDM 
4IDDM 15 Control 
53 IDDM 
53 Control 
10 Control 
10 IDDM 
35 Control 
18 T2DM 
Diabetic 
Retinopathy 
noted 
nil 
nil 
nil 
noted 
nil 
nil 
nil 
nil 
Duration 
of DM 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
Control of 
DM 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
noted  
Type of 
DM 
T1DM 
and 
T2DM 
T2DM 
T1DM 
IDDM 
IDDM, 
NIDDM 
T1DM 
and 
T2DM 
T1DM 
IDDM 
T2DM 
Author and Year 
Rajewski et al., 2007 
Dolu et al., 2003 
Verrotti et al., 2000 
Parisi et al., 1998 
Azal et al., 1998 
Raman et al., 1997 
Seidl et al., 1996 
Parisi et al., 1995 
Moreo et al., 1995 
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P100 peak time 
significant delay in both 
diabetic groups 
increased P100 in diabetics 
increased peak time P100 
P100 significantly delayed in 
diabetics 
delayed VEP P100 in diabetic 
group 
increased P100 peak time  
increased peak time of P100 
in diabetic group 
Number 
of Participants 
10 Control 
10 T1DM 
12 Control 
7 IDDM 
35 Control 
15 T1DM 
54 Control 
31 T1DM 
19 T2DM 40 Control 
11 IDDM 
36 Control 
50 T1DM 
35 Control 
16 DM 
Diabetic 
Retinopathy 
nil 
noted 
nil 
noted 
nil 
nil 
nil 
Duration 
of DM 
noted 
noted 
noted 
noted 
noted 
noted 
noted 
Control of 
DM 
not noted 
noted 
noted 
noted 
noted 
noted 
noted 
Type of 
DM 
T1DM 
IDDM, 
NIDDM 
T1DM 
and 
T2DM 
T1DM 
and 
T2DM 
IDDM, 
NIDDM 
T1DM 
not 
noted 
Author and Year 
Uccioli et al., 1995 
Ziegler et al., 1994 
Mariani et al., 1990 
Algan et al., 1989 
Pozzessere et al., 1988 
Anastasi et al., 1985 
Puvanendran et al., 1983 
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2.2 Investigating the effects of DM and the CNS 
 
The literature review revealed that although the peripheral nervous system (PNS) in DM has 
been extensively investigated, the pathophysiology of the CNS abnormalities associated with 
DM is still not well understood because few researchers have focused on this specific aspect 
in their studies as explained by Dolu et al. (2003). These authors support the statement of 
Moreo et al. (1995) who observed that in the nineties the neuroretinal function and the 
effects of DM on the CNS was an area that had received far less investigation than the 
pathophysiology of the PNS. In the same timeframe Dejgaard et al. (1991) found the use of 
neuroimaging techniques provided evidence that DM causes structural changes in the brain 
thereby confirming it is a long-term complication of DM and the CNS is indeed affected. 
 
Imaging technology such as magnetic resonance imaging (MRI) principally remains an 
imaging, structural or anatomic evaluation revealing information about structural anomalies. 
Evoked potential (EP) testing determines functionality. Although it provides some insight into 
the physiology of a certain anatomic pathway, the understanding is less than the spatial or 
localising information provided by an MRI (Alessandrini et al., 1999).  
 
It is therefore posited in this study that visual abnormalities in DM should be seen in the 
context of visual function: starting with the anterior chamber of the eye (including the retina, 
optic nerve, central pathways and occipital cortex) and ending up requiring higher cerebral 
function to perceive and respond to the stimulus. 
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2.3 Investigating the effect of DM on VEP 
 
Electrophysiological investigation using visual evoked potential (VEP) is a very simple, 
sensitive and objective technique for evaluating impulse conduction along the CNS pathways 
(Azal et al., 1998). Visual loss resulting from DM occurs due to vascular disease as well as from 
metabolic anomalies affecting the retina and the visual pathways. VEP appraises the integrity 
of the neural pathways used for vision and is therefore an effective gauge of incipient visual 
changes in DM (Gayathri et al., 2012). 
 
Increased peak time of the visual P100 waveform as observed in DM is an expression of 
structural damage at the level of myelinated optic nerve fibres (Bhanu et al., 2012; Azal et al., 
1998). VEP is useful in diagnosing peripheral as well as central neuropathy in DM (Algan et al., 
1989; Abraham et al., 1986). Many patients exhibit normal clinical examinations but show a 
decrease in nerve conduction velocity. The neural retina of diabetic eyes experience subtle 
functional changes before any microvascular lesions are detected by fundus photography 
(Lieth et al., 2000). Peak time delay of the VEP is a specific finding that evidences 
demyelinating diseases (Dolu et al., 2003; Cerizza et al., 1990; Carsten et al., 1989).  
 
Two studies conducted in the mid to late 1990s (Azal et al., 1998; Moreo et al., 1995) reveal 
the P100 wave peak time were significantly larger in study patients with new onset non-
insulin dependent diabetes mellitus (NIDDM) when compared with healthy control subjects. 
Moreover, the findings indicate optic nerve involvement may develop in patients with NIDDM 
even before the onset of any symptoms. 
 
An interesting result occurred when the findings of various previous studies on the use of VEP 
and DM were investigated: the congruent finding was that, when compared to non-diabetic 
control participants, diabetic participants exhibited a definite increase in the P100 peak time 
(Kumar et al., 2014; Bhanu et al., 2012; Gayathri et al., 2012; Chopra et al., 2011; Algan et al., 
1989). Of note though is that the percentages of participants who presented with abnormal 
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results differed quite significantly among the different study findings. It is proposed that these 
disparities were due to the differences in study populations and methods. 
 
Ewing et al. (1998) state there is conclusive evidence showing abnormalities occur in the P100 
waveform in DM before the development of retinopathy in newly diagnosed patients with 
IDDM when compared with those who have long-standing DM, as corrections of the blood-
glucose levels improve P100 peak time delay measurements, however the P100 peak time 
values of long-standing DM, remained significantly delayed when compared to non-diabetic 
values. These researchers conducted a study on electrophysiological and psychophysical 
abnormalities and alterations in the vision of DM participants. They discovered a discrepancy 
exists as to whether there is a correlation as found by their study, with recent metabolic 
control and P100 wave peak time in poorly controlled DM.  
 
Several studies have investigated the relationship between DM duration and P100 peak time. 
The Diabetes Control and Complications Trial (DCCT) Research Group (1993) reported 
conflicting information regarding this. Perros et al. (1996) further observe there are 
conflicting reports with regard to the abnormal VEP results in diabetic participants who did 
not have retinopathy. Despite some insightful findings, Perros et al. (1996) suggest the 
evidence found pertaining to the relationship between the duration of diabetes and VEP 
abnormalities has been limited. On the contrary, Ewing et al. (1998) state that a clear 
distinction has not been made between the diabetic types, duration of DM, presence of 
complication, visual acuity and quality of glycaemic control for the inclusion criteria of study 
subjects in many studies that compared the P100 peak time in DM. 
 
In a more recent study Kumar et al. (2014) found VEP anomalies resulted from poor control 
and long duration of the disease. Both these factors correlated with significant VEP peak time 
delay as well as having a decreased amplitude of the waveform. Participants consisted of 40 
T2DM without retinopathy and 40 T2DM with non-proliferative diabetic retinopathy (NPDR). 
The duration of diabetes varied in both groups from one to 10 years. A control group of 40 
healthy non-diabetic patients was also investigated. Kumar et al. (2014) conclude their study 
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by stating as soon as tight metabolic control is achieved, the VEP abnormalities correct 
themselves. The authors suggest that this is because of these correlations taking place that 
VEP impairment is only functional and completely reversible. However Kumar et al. (2014) 
confirms that, VEP assessment is essential for the uncovering of pre-retinopathy changes that 
take place; it is plausible to reduce DM complications by using VEP as a testing procedure for 
diabetics. 
 
The percentages of participants presenting with increased P100 peak time among the various 
studies examining VEP abnormalities as a consequence of DM range from 9 – 77% (Mariani 
et al., 1990; Algan et al., 1989; Anastasi et al., 1987; Ponte et al., 1986; Cirillo et al., 1984; 
Puvanendran et al., 1983). Collier et al. (1988) state they did find VEP abnormalities in diabetic 
patients with retinopathy but no abnormalities were found in any diabetic patients who did 
not have retinopathy. However, the findings of Mariani et al. (1990) indicate a prolongation 
of the P100 peak time in diabetic patients with no retinopathy present. 
 
Uccioli et al. (1995) report impaired P100 peak time in VEP in newly diagnosed IDDM patients. 
Some research studies report a correlation between recent metabolic control and P100 wave 
peak time in diabetic patients, but not all the studies reviewed concur (Azal et al., 1998; 
Ziegler et al., 1994; Algan et al., 1989; Pozzessere et al., 1988).  
 
Ponte et al. (1986) report there was an increase in the P100 peak time of 50 subjects with 
asymptomatic T1DM who had no retinopathy while Millinger et al. (1987) established that 
abnormal VEP can reflect maculopapular fibre or optic nerve involvement. More recently, in 
their study comprising 20 T1DM participants with no diabetic retinopathy (DR) Shrivastava et 
al. (2014) found results similar to those of Ponte et al. (1986). The diabetic participants in the 
study done by Shrivastava et al. (2014) exhibited a significant delay of the P100 as well as a 
correlation between the delay of the P100 and the duration of disease. However, they did not 
find a significant connection between the P100 peak time and the glucose level of the diabetic 
participants. 
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Central neuropathy in DM has not been appreciated as long as peripheral neuropathy has 
been. Describing clinical and pathological evidence for a diabetic myelopathy and 
encephalopathy, De Jong (1977) explains it was found that changes in the optic nerves 
occurred as frequently as changes in the peripheral nerve in DM; yet, there was no clinical 
evidence in any of the reviewed study cases of optic neuritis and the individual patients’ visual 
acuity was normal. 
 
Heravian et al. (2012) discovered abnormal peak time of the P100 wave in 60% of their DMT2 
participants when compared to the control group. Forty diabetic patients (consisting of 20 
diabetics having NPDR and 20 diabetic participants without NPDR) and a control group of 40 
healthy, non-diabetic participants took part in this study. Interestingly, for both of the diabetic 
groups the peak time of the P100 wave was significantly delayed – even for those with no 
diabetic retinopathy. It was therefore concluded that an increased peak time of the P100 as 
observed in diabetic subjects can be interpreted as structural damage to the myelinated optic 
nerve fibres and, therefore, dysfunction of the CNS. Visual evoked potential can thus ascertain 
preclinical microvascular as well as neurodegenerative effects within the retina and along the 
visual tracts. 
 
Li et al. (2001) report VEP irregularities in DM associate well with hyperglycaemia. Raman et 
al. (1997) found similar results to that of Al-idani et al. (2009) in that a positive correlation 
existed between glucose control and delayed P100 peak time, however no correlation was 
found in these two studies relating to duration of disease. However, Heravian et al. (2012) do 
not recognise the correlation between blood glucose levels and P100 wave peak time in 
diabetic participants as it did not reflect in their findings and neither did any association 
between the duration of diabetes and P100 wave peak time. 
 
Bhanu et al. (2012) conducted a study with 20 participants with NIDDM and concluded the 
observed prolongation of P100 peak time could be the consequence of structural damage at 
the myelinated optic nerve fibres level or retinal ganglion cell damage in advance of possible 
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progression of diabetic retinopathy. Of note is that this particular study showed a compelling 
positive correlation with P100 peak time and the duration of DM, as did Seidl et al. (1996). 
 
A significant correlation between the P100 peak time and the duration of DM was also 
observed by Chopra et al. (2011). These researchers concluded that VEP measurements in 
DM can be used to make an early diagnosis of central neuropathy thereby ensuring prompt 
medical care. Type 2 diabetes mellitus (T2DM) participants with different durations of the 
disease were used in the mentioned study by Chopra et al. (2011); however, there is no 
mention made in the method of glycaemic control of the participants. To determine if a 
correlation exists between the duration of DM and a prolonged P100 waveform, the blood 
glucose levels should be analysed as this will allow for a more decisive correlation to be 
adopted. 
 
2.4 Rationale for study methodology 
 
The majority of the studies reviewed with regard to examining the effects of DM and VEP 
report a significant increase in the P100 peak time of diabetic participants when compared to 
their non-diabetic controls. In fact, the different methodologies employed by the various 
research studies reviewed made it difficult to compare the study results and findings obtained 
because in many of them no distinction is made between the type and duration of DM, the 
presence of ophthalmic and neurological pathology, and the quality of glycaemic control. 
 
There is a need to investigate the effect of the DM type, duration of diabetes, visual acuity, 
and level of glycaemic control on VEP whilst controlling for other ocular and neurological 
pathologies. Making use of two groups of participants and comparing poorly controlled HbA1c 
10% and above measurements to the moderately controlled HbA1c 10% and less, will expand 
on the existing knowledge. 
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2.5 Summary 
 
This chapter covered the literature review relevant to the association between DM and VEP. 
The rationale for the study design was discussed. In the next chapter the methodology of the 
study will be described in detail. 
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Chapter Three 
Methods 
 
In the previous chapter research relating to DM and VEP was presented. In this chapter the 
methods of the study will be covered. These will be based on the literature review studied 
from previous research to narrow the gaps in current knowledge. 
 
3.1 Study design 
 
An observational cross sectional study design was selected to observe the PVEP results of 
non-diabetic control and diabetic participants. The control participants were investigated in 
Phase 1 of the study and the diabetic participants in Phase 2. Observational cross sectional 
studies do not require follow-up consultation as data are obtained in a single, once-off 
consultation (Hennekens & Buring, 1987).  
 
3.2 Aim of study 
 
The objectives were to: 
 
 determine whether there is a possible association between the P100 peak time of 
visual evoked potential (PVEP) and the glycated haemoglobin percentage  
 to establish whether the central nervous system (CNS) in particular visual function is 
affected, resulting in DM-related central neuropathy as well as to the type of diabetes 
involved and the duration that the participant has been diagnosed as a diabetic. 
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3.3 Study plan 
 
The study consisted of two phases.  
 
In Phase 1 the aim was to determine the standards for the normal range of the PVEP 
instrumentation and thus determine the normative values for the P100 for this study. For the 
first phase healthy non-diabetic participants were recruited. 
 
Phase 2 involved the recruitment of diabetic participants. These diabetic participants had 
been medically classified as either T1DM or T2DM. Particular attention was paid to the 
participants’ glycated haemoglobin percentages. The diabetic participants were then formed 
into two groups: those having an HbA1c greater than 10% and those whose HbA1c was 10% 
and less (moderate control vs. poor control).  
 
3.4 Setting 
 
The study was conducted at the practice of Nagle and Louw Optometrists. The location is 12 
Glen Gables, corner of Lynnwood Road and January Masilela Drive, Lynnwood Glen, Pretoria, 
Republic of South Africa (RSA). The above mentioned practice is an independent optometric 
practice owned and managed by the principal investigator, Mark Nagle. 
 
3.5 Ethics 
 
The Aston University Ethical Committee approved the conduction of this study on 10 April 
2013. (See Appendix A1 - Ethics Application 421).  
 
Permission to conduct the study was sought from the Pharma-Ethics Ethics Committee. 
Pharma-Ethics is an independent research ethics committee in the Republic of South Africa. 
Permission to conduct this study in the RSA was granted by the committee. (See Appendix 
A2). 
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3.6 Recruitment of participants 
 
Recruitment was carried out in collaboration with Professor James Ker who is a specialist 
physician/cardiologist having his own private medical practice. This collaboration was 
necessary as it is beyond the scope of practice for an optometrist to order an HbA1c blood 
test. 
 
The participants remained under the medical care of Professor Ker throughout the time of 
this study – from the time they were recruited until the study was completed. 
 
The design of the study, data collection, data entry, data analysis and write-up were done by 
the optometrist, Mark Nagle.  
 
3.7 Informed consent 
 
Ethical considerations as well as the study procedures were explained to every potential 
participant individually before enrolment. It was explained to each individual that they had 
the right to choose to participate or decline participation without prejudice. If an individual 
chose to participate, he or she was advised that withdrawal from the study at any time was 
an option that would not be disputed or queried.  
 
All questions from the participants were answered and queries clarified. They were made 
aware of their rights as participants, e.g. to willingly participate or decline participation 
without prejudice. They were assured their identities would remain anonymous and all data 
would remain confidential. Those who then voluntarily decided to participate in this study 
were requested to complete and sign a participation consent form. After signing the informed 
consent form, they were then included as participants in the study. Vulnerable groups, 
namely, children and mentally incapacitated participants, were not considered for 
participation or recruited as participants in this study.  
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Professor Ker kept the study data, relevant notes and original record file of each participant 
safely and securely locked away in his practice. Every individual participant was allocated a 
code (a computer generated file number) to guarantee her or his anonymity. Confidentiality 
of the participants’ details as well as the data collected from them was upheld throughout 
the study process. These documents were transferred via e-mail and will be retained for a 
minimal period of 15 years. Calculation as to the time-period of 15 years was started after the 
last consultation .  
 
3.7.1 Sample sizes. 
 
The sample sizes for Phases 1 and 2 of the study were determined using nQueryAdvisor 7.0 
Statistical Solutions Ltd. software – a one-sided testing using Fisher’s exact test. 
 
A sample of at least 30 participants is required to determine the normal range for P100 peak 
time from a control group. Accordingly, to determine the normal range for P100 peak time a 
sample of at least 30 participants is needed to be assessed. The determination of cut-off 
values to define the normal range assumes an underlying Gaussian distribution of the data. 
By convention this is a reasonable assumption when the sample size is at least 30. By making 
use of the Shapiro-Wilks test for normality (see Chapter 4), the P100 peak time values for 
both right and left eye did not deviate from a Gaussian distribution with p-values of 0.90 and 
0.45 respectively.  
 
For Phase 1 the control group comprised of 30 healthy non-diabetic participants. It was 
considered appropriate to compare two groups of participants, a moderate to good control 
group and a well-controlled group, to the mean control P100 peak time and also to the 
proportion of participants with delayed P100 peak time, i.e. the P100 peak time in excess of 
mean plus 2.5 standard deviation for the control group. 
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The sample size for Phase 2 was based on the comparison of proportions since a larger sample 
size than for a comparison of means is required. The proportions of participants with delayed 
P100 peak time in the moderate to well-controlled groups were expected to be about 30%. 
However, a sample size of 52 participants per group would have 90% power to detect a 
clinically relevant twofold increase in the poor control groups, i.e. 60%, using nQuery Advisor 
7.0 Statistical Solutions Ltd. software. 
 
3.7.2 Inclusion criteria for Phases 1 and 2 
 
The inclusion criteria for both phases of the study were similar. 
 
 Participants had to be older than 18 years. 
 Both male and female participants were included as participants.  
 All ethnic groups were included. 
 A minimum visual acuity of 6/9 for distance and N5 for near for each eye (aided or 
unaided). 
 
3.7.3 Exclusion criteria for Phases 1 and 2 
 
The exclusion criteria for both phases of the study were similar. 
 
 Participants presenting with ophthalmic pathology such as any media opacities in the 
anterior aspect of the eye (cornea, anterior chamber and crystalline-lens) as well as 
any posterior chamber media opacities (clear vitreous). 
 All retinal pathologies (diabetic retinopathy, ARMD, retinal detachments to name a 
few) led to exclusion.  
 Neuro/ophthalmic pathologies such as glaucoma led to exclusion. 
 All neurological medical conditions such as multiple sclerosis (MS) led to exclusion 
from the study. 
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3.8 Study procedures 
 
Phase 1 of the study was done with 30 healthy non-diabetic participants. In this phase the 
standards for the normal range of the PVEP instrumentation, therefore the normative values 
for the P100 waveform for this study, were determined. The results from the recent HbA1c 
blood tests of these 30 participants confirmed their HbA1c was between 4% and 5.9%. These 
results confirmed their non-diabetic status. 
 
Phase 2 of the study was done with 104 diabetic participants. The diabetic participants were 
divided into two groups: group one comprised of 52 participants who had an HbA1c greater 
than 10% and group two consisted of 52 participants whose HbA1c measured 10% and less. 
 
3.9 Data collection protocol Phases 1 and 2 
 
 Confirmation of HbA1c measurement. 
 Confirmation of signed informed consent forms. 
 A comprehensive medical history taking that included making notes of all types of 
medications taken. 
 Comprehensive ocular examination:  
o Including unaided visual acuities, ocular motilities, retinoscopy, pupil reactions, 
a subjective refraction, colour vision screening using an Ishihara 
pseudoisochromatic 24 plate, an Amsler Grid test, and a confrontational visual 
field screening. 
o A slit-lamp examination (Nikon NS IV) was performed starting with the 
lids/lashes, sclera, conjunctiva, and the cornea to examine the anterior 
structures of the eye. An anterior chamber depth grading was done using the 
Von Herrick technique. The crystalline lens examination from the anterior 
aspect to the posterior section with any media opacity was carefully 
documented. 
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o A posterior ocular examination was performed using both a direct and an 
indirect ophthalmoscope. An indirect ophthalmoscopy was performed using a 
Volk super field non-contact slit-lamp lens that enabled an undilated 95 degree 
field of view with a 0.76X magnification. 
o An applanation tonometry (Nikon NS IV) was performed after instilling one drop 
(0.4%) Novesin Wander (Restan) in each eye. Three readings were taken for 
each eye. No fluorescein was instilled for this procedure. 
o Fundus photography was done using a Topcon TRC NW200 (non-mydriatic 
retinal camera). All four retinal quadrants, i.e. superior nasal, inferior nasal, 
superior temporal and inferior temporal were photographed as well as the 
posterior pole for each eye. 
 
3.10 Visual evoked potential (VEP) test methods Phases 1 and 2 
 
3.10.1 Research VEP training 
 
Basic PVEP usage was demonstrated by the Nihon Khoden agents before the study 
commenced. A qualified and registered neurophysiologist assisted in further PVEP usage 
training to ensure compliancy before the study began. The same neurophysiologist acted as 
the overseer of the control group during Phase 1 of the study. 
 
3.10.2 VEP instrumentation room set-up 
 
The main optometric consulting room was used to house the VEP unit. A Nihon Kohden (MEB 
9400) neuropak (S1) 2-channel amplifier was used for storing and summating the waves. A 2-
channel unit is used to measure the prechiasmal parts of the visual pathway, namely, the 
retina and optic nerve. Nihon Kohden neurophysiological technicians ensured that all the 
necessary installation and calibration procedures of the VEP unit were carried out in 
accordance to the (ISCEV Guideline 9B, 2008). 
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The temperature in the consulting room was kept to a constant 22°C. The air conditioner unit 
did not interfere with the noise level in the room. Additionally, all noise artifacts were 
removed from the room as measured with a Mastech (MS 6700) auto ranging digital sound 
level metre. 
 
To ensure an equal darkened room for all participants, the room illumination was adjusted 
from one single light source to a pre-set rheostat level of 10 Lux. All other light sources from 
instrumentations were switched off. The room luminance was determined by measuring the 
luminance at four positions with a hand-held photometer (Goldilux) within 1 m from the 
stimulus-screen. The average of these measurements was used for the study. Each participant 
was given 5 minutes to adapt to the darkened light level in the room before the PVEP test 
began. No mobile phones or any other distracting devices were allowed in the main 
optometric consulting room. 
 
 
Figure 3.1: PVEP participant set-up 
 
3.10.3 PVEP screen 
 
An Esquire 17-inch cathode ray tube (CRT)-60HZ screen (dimensions 330 mm x 275 mm) was 
used to display the stimulus. The screen was positioned 1 m from the seated participant 
resulting in a visual angle of 18.33 °and a check size of 1.164 °.The visual angle describes the 
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size of the image of one light or dark element at the retina and this commonly indicates the 
size of the squares on the checkerboard pattern. 
 
The brightness as well as the contrast controls of the display screen were covered to prevent 
accidental adjustment thereby ensuring the same settings were used from the start of the 
study to its completion.  
 
A screen stimulus luminance of 60 cd/m2with a high contrast of 80% was maintained for all 
participants in this study. 
 
In pattern-reversal PVEP the stimulus consists of a sudden change of all light pattern elements 
into dark ones and vice versa. This is used to avoid overall luminance changes. There was no 
overall change in the mean luminance of the screen during pattern-reversal. This is pivotal for 
PVEP as the peak time of the response increases when the mean luminance is decreased 
(Brigell et al, 2003).  
 
The mean luminance of the stimulus screen was inspected after every 10 participants to 
ensure consistency in the study. A sheet of white paper was held in front of the stimulus-
screen (distance 0.5 m from the screen) and with the lights set to testing conditions (10 Lux). 
The reflection of the black and white changing checkerboard did not indicate any transient 
luminance change with the pattern shifts. 
 
3.10.4 PVEP instrument recording parameters 
 
The electrode impedance did not exceed 5 kΩ. 
 
Full field stimulus was employed; thus, the stimulus pattern was equal to both sides of the 
fixation point on the display screen. Full field testing is most sensitive in detecting changes in 
the visual system anterior to the optic chiasm. The checkerboard pattern-reversal consisted 
of black and white square checks numbering 16 x 12, measuring 19 mm x 19 mm, and having 
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a 4:3 width-to-height aspect ratio. Visual fixation was at the centre of the display screen. The 
reversal rate of 2 reversals per second was used to elicit the PVEP. 
 
The bioelectrical signal was amplified and filtered by band-pass filters of 1-100HZ (1HZ = Lo-
cut; 100HZ = Hi-cut). With automatic rejection of artifacts and excluding artifacts given to each 
eye it averaged over 100 stimulus periods. This was repeated twice and the averages of the 
two waveforms were superimposed to demonstrate reproducibility. The signal-to-noise ratio 
was set at 5 microvolts.  
 
The analysis time was 250 ms as this is the standard for transient PVEP for normal adults. For 
children and adult individuals with abnormally delayed PVEP, 500 ms is employed (Odom et 
al., 2009).  
 
3.10.5 PVEP waveform and markings 
 
The polarity refers to the positivity and negativity between the two electrodes connected to 
the inputs of the recording system. The relationship between the electric potential changes 
at the electrodes and the upward and downward deflections of the evoked potential tracing 
depends on where the electrode is connected (ISCEV, 2009).  
 
The polarity convention used for this study was placing the positive (or active) electrode on 
the OZ occipital region and the negative reference electrode on the Fpz region 12 cm above 
the nasion. These electrode placements resulted in an upward deflection as a positive 
waveform (P100) and a downward deflection as a negative waveform (N75 and N145).  
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Figure 3.2: PVEP waveform demonstrating polarity 
 
3.10.6 Participant preparation for PVEP test 
 
The participant preparation was done in accordance with the ISCEV Standards (2009).  
A 10-minute time interval was given to allow the participant time to recover from the eye 
test. None of the participants had their pupils dilated because an altered pupil size may 
change the stimulus luminance thereby affecting the PVEP amplitude and peak time. No 
participants presented with abnormal pupil sizes or with anisocoria. 
 
The placing of the electrodes as well as the nature of PVEP testing was explained to each 
participant. A nylon 150 mm tape measure was used to take the participant’s head 
measurements and markings on the scalp were made with a red greaseless marker pencil. 
These markings for placement of the electrodes were in accordance with the International 
10/20 System (ISCEV Standards, 2009) as shown in Figure 1.2. 
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As shown in Figure 3.3 silver-silver chloride recording electrodes were placed on the scalp at 
the following reference points: 1) (Oz) occipital region for recording electrode; 2) the 
reference electrode (Fpz) frontal or 12 cm above the nasion; 3) the ground electrode placed 
at the vertex (Cz). 
 
 
Figure 3.4:Electrode placing on participant 
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The International 10/20 System is established on head-size measurements (Jasper, 1958). The 
mid-occipital electrode location (Oz) is on the midline. The distance above the inion is 
determined by 10% of the distance between the inion and the nasion (for most adults this 
distance measures 3 – 4 cm). 
 
The location of the ground electrode (CZ) was marked as 40% of the inion-nasion distance 
above OZ. On average this is 11 cm above the nasion for the 10/20 System (Chatrian et al., 
1980). The reference electrode was placed on the right forehead area (Fpz).  
 
The polarity of Oz  was positive and that of Cz negative resulting in the upward deflection of 
the P100 evoked potential and a downward deflection of the N75 and N145 evoked 
potentials. 
 
Nihon Kohden Skinpure 135 g scalp preparation gel Y2-0019 was used to clean the scalp and 
remove dead skin cells and oils. To apply the electrodes, Nihon Kohden Elefix EEG contact 
paste Z-401CE was applied on the marked electrode locations to make sure a good, stable 
electrical connection between the scalp and the electrodes was made. Each electrode was 
pressed firmly into the Elefix contact paste onto the scalp. Micropore gauze was placed on 
top of the active electrodes to ensure their contact was maintained. 
 
 
Figure 3.5: VEP participant preparation 
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The participant was comfortably seated at a distance of 1 m from the PVEP display screen. 
The distance was measured with a metre stick from the orbit to the centre of the display 
screen. The 1 m distance was maintained throughout the examination of each participant. 
 
An eye patch with gauze (secured with a 24 mm x 10 m 3M Micropore 1530 dressing tape) 
was placed over the non-testing eye. It was explained to each participant that the occluded 
eye should not have to be forced closed by the eyelid and the natural blink reflex should 
continue under the eye patch. Therefore, each participant was asked if the occluded eye could 
see anything. For both Phases 1 and 2 the left eye of each participant was occluded first. 
 
The electrode impedance was checked after the placements of the electrodes and again after 
the eye patch had been applied. If spectacles were worn it was placed over the eye patch. The 
electrode impedance did not differ by more than 20% between electrode sites (Oz and Fz) as 
seen in the image screen shot below.  
 
Figure 3.6: Electrode impedance screen shot 
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At the end of each procedure the participant’s hair and scalp was cleaned of all the contact 
paste and the head markings made with the greaseless marker pencil. Each cup-shaped silver-
silver electrode was scrubbed and washed with 0.5 g chlorhexidine and 70 ml propyl alcohol 
solution to ensure sterility before being reused. 
 
3.10.7 PVEP instructions given to participants 
 
The principal investigator, Mark Nagle, requested each participant to make sure she or he was 
feeling as comfortable and relaxed as possible when viewing the checkerboard screen. The 
participant was further requested to maintain a normal blink rate to ensure a clear optical 
image. Also, if the participant experienced any discomfort and/or defocus she or he was to 
mention it. The participant was assured that, if this should occur, the PVEP test would be 
paused so that she or he could regain her or his focus and concentration. 
The participants were instructed to maintain their focus on the central white block in the 
middle of the display screen. They were encouraged to keep a silent count on the rate of the 
alternating black and white checks to help maintain their visual concentration. 
 
No PVEP test was started before the participant had confirmed that he or she was ready and 
comfortable to begin. 
 
3.11 Data analysis 
 
For the analysis of the gathered data, the Stata Release 11 (Stata Corp LP, 2009) statistical 
software program was used. 
 
The P100 peak time and HbA1c of the study groups were summarised using descriptive 
statistics thereby including the mean, the standard deviation, and the range. The cut-off value 
for delayed P100 peak time was determined as the mean +2.5 x standard deviation for the 
control group. The cut-point calculation assumes an underlying Gaussian distribution which 
was confirmed with the Shapiro-Wilks test for normality. Reliability was confirmed by doing 
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a second reading for 15 randomly selected participants from the control group. This second 
reading was done by repeating the whole PVEP procedure for the control group. The reliability 
was measured by the intraclass correlation coefficient (ICC) that was determined from a 
random effects maximum likelihood regression analysis. 
 
With respect to the P100 peak time category (not delayed/delayed), the diabetic groups were 
compared using logistic regression and Fisher’s exact test. From this logistic regression odds 
ratios along with 95% confidence intervals were reported.  
 
For the comparison of the control and diabetic groups, a regression analysis, the analysis of 
covariance age was employed. Analysis of covariance (ANCOVA) with covariate age was used 
to determine the effects from this regression analysis. Testing was at the 0.05 level of 
significance. 
 
3.12 Summary 
 
This chapter described the design for this cross sectional study during which the possible 
association between the P100 peak time of pattern-reversal visual evoked potential (PVEP) 
and the glycated haemoglobin percentages were investigated. It included the study plan, a 
full description of the recruitment, the requirements for PVEP testing, and the preparation of 
the participants for this testing. The setting and instrumentation set-up for PVEP were 
described in detail. Ethical approval to conduct the study in the RSA was noted.  
 
The next chapter will present the repeatability and reliability of Phase 1 – the non-diabetic 
control participants’ PVEP findings as well as to determine the cut-points determining normal 
from delayed P100 peak time measurements for the DM groups. 
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Chapter Four 
Reliability Analysis 
 
The methods used to conduct this study were presented and discussed in the previous 
chapter. The participant selection, setting, PVEP testing were, inter alia, described in depth. 
It was further confirmed that ethical approval to conduct this study in the Republic of South 
Africa was obtained.  
 
This chapter concerns the repeatability and reliability of the data analysis of Phase 1 that 
involved the non-diabetic participants. 
 
4.1 Phase 1 – Reliability assessment of the non-diabetic group 
 
Thirty non-diabetic participants were enrolled in Phase 1 of the study. The participants 
consisted of 10 males and 20 females with a mean age of 32.6 ± 8.52 years. The mean HbA1c 
values of 5.38% ± 0.17 confirmed all 30 participants’ non-diabetic status (Koenig et al., 1976). 
The entire and exact PVEP testing procedure was repeated with each of 15 participants. Thirty 
observations is generally accepted to conform with the normal distribution theory (Pagano, 
2004).  
 
Repeatability of the P100 measurements was assessed in a subset of 15 control participants 
with the intraclass correlation (ICC) (on a scale of 0 to 1 where 1 represents perfect reliability 
and with no measurement error and 0 indicates no reliability) using random-effects maximum 
likelihood regression. The observations are displayed in Table 4.1. 
 
The ICC equation used for this study was: ICC = (mean squares between patients – mean 
squares within patients)/(mean squares between patients + mean squares within patients). 
The ICC was the preferred reliability statistical analysis test for this study because intrarater 
agreement is best measured by ICC (Lachin, 2004). 
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Table 4.1: ICC as measure of repeatability of waveform markings P100, N75, N145 and amplitude – 
control (non-diabetic) group – Phase 1 
Waveform 
ICC 
Right Left 
P100 0.928 0.831 
N75 0.820 0.844 
N145 0.931 0.931 
Amplitude 0.933 0.933 
 
Considering an ICC of 0.9 as excellent, the repeatability of the PVEP results for VEP unit (Nihon 
Kohden MEB 6400K) displayed in Table 4.1 was acceptable for this sample. 
 
4.2 Normative data 
 
The cut-points for PVEP peak time to determine normal from delayed peak time were 
determined as mean +2.5 x standard deviations, where exceeding the cut-point will imply 
delayed PVEP peak time. (See table 4.4; 4.5; 4.6; 4.7). The latter calculation assumed an 
underlying Gaussian distribution which was confirmed by the Shapiro-Wilks test for normality. 
The result confirms that the underlying distribution did not deviate from the Gaussian 
distribution for both the right and left eyes. 
 
Table 4.2: Cut-point measurements for delayed peak time P100, N75, N145 – control (non-diabetic) 
group – Phase 1 
 Right (ms) Left (ms) 
P100 110.64 111.86 
N75 85.70 79.70 
N145 157.02 158.97 
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Table 4.3: Shapiro-Wilks test for normal data p-values – control (non-diabetic) group –  
Phase 1 
Variable Observations Right p-value Observations Left p-value 
P100 30 0.90 30 0.45 
N75 30 0.20 *28 0.14 
N145 30 0.85 30 0.21 
 
The left N75 produced an original p-value of 0.00071 using 30 observations; the data thus 
deviated from normality. Two outlier measurements of 81 ms and 89 ms respectively were 
identified and removed, resulting in a new but not significant p-value of 0.14 thereby showing 
that the new data did not deviate from normality. 
 
4.3 Summary statistics P100 – control (non-diabetic) group – Phase 1 
 
The right and left eyes did not differ significantly with respect to the P100 (p = 0.63; student’s 
paired t-test). 
 
Table 4.4: Descriptive statistics for P100 peak time – control (non-diabetic) group – Phase 1 (N = 30) 
Side Mean (ms) Standard deviations Min (ms) Max (ms) 
Right 101.22 3.77 92.7 109.5 
Left 101.00 4.35 88.5 109.2 
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4.4 Summary statistics N75 – control (non-diabetic) group – Phase 1 
 
The right and left eyes did not differ significantly with respect to the N75 (p = 0.39; student’s 
paired t-test). 
 
Table 4.5: Descriptive statistics for N75 peak time – control (non-diabetic) group – Phase 1 (N = 30) 
Side Mean (ms) Standard deviations Min (ms) Max (ms) 
Right 72.80 5.16 63.9 85.2 
Left 71.44 3.30 67.2 78 
 
4.5 Summary statistics N145 – control (non-diabetic) group – Phase 1 
 
The right and left eyes did not differ significantly with respect to the N145 (p = 0.30; 
student’s paired t-test). 
 
Table 4.6: Descriptive statistics for N145 peak time – control (non-diabetic) group – Phase 1 (N = 30) 
Side Mean (ms) Standard deviations Min (ms) Max (ms) 
Right 133.50 9.41 114.3 155.1 
Left 132.54 10.57 114 151.5 
 
4.6 Summary statistics amplitude – control (non-diabetic) group – Phase 1 
 
The right and left eyes did not differ significantly with respect to the amplitude (p = 0.35; 
student’s paired t-test). 
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Table 4.7: Descriptive statistics for Amplitude – control (non-diabetic) group – Phase 1 (N = 30) 
Side Mean (μV) Standard deviations Min (μV) Max (μV) 
Right 12.67 5.52 4.7 25.5 
Left 12.28 5.33 4.2 25.5 
 
4.7 Summary 
 
The reliability and repeatability of the data obtained from Phase 1, the non-diabetic control 
group, were assessed. The cut-points to determine normal from delayed P100 peak time for 
the DM group was established as right eye 110.64 ms and left eye 111.86 ms.  
The next chapter will focus on Phase 2 of the study. It will include a data analysis of the 
diabetic group and the results of this study on DM groups. 
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Chapter Five 
Results 
 
The previous chapter covered the reliability and repeatability of the data obtained and 
analysed in Phase 1 – the non-diabetic control group of this study. The P100 peak time cut-
points was established from the non-diabetic control group to distinguish the normal from 
the delayed P100 peak time. This chapter presents the results of the study of the DM groups. 
 
5.1 Phase 2 – Diabetic group analysis 
 
The results for this group are represented by data of the right eye only, as it has been 
demonstrated in chapter 4 that no statistical difference was found between the PVEP values 
of the right and left eyes. 
 
The moderately controlled DM group (6.5% < HbA1c ≤ 10%) consisted of 52 participants; 33 
males and 19 females. The mean age for this group was 56.1 ± 13.04 years and the mean 
duration in years for this group was 7.8 ± 5.9 years. The poorly controlled DM group (HbA1c 
> 10%) comprised of 52 participants: 29 males and 23 females. The mean age for this group 
was 45.2 ± 12.68 years and the mean duration in years for this group was 9.1 ± 6.3 years. DM 
group (moderate;poor) differed significantly with respect to age (Student’s two-sample t-test: 
p< 0.001) but not with respect to disease duration (Student’s two-sample t-test: p = 0.294).  
Furthermore the DM groups also did not differ with respect to gender distribution ( Fisher’s 
exact test: p = 0.549 Males: 63.5% (33/52) vs 55.8% (29/52)or Females: 36.5% (19/52) vs 44.2% 
(23/52)). 
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Table 5.1: Participant demographics – diabetic groups 
HbA1c > 10% 6.5% < HbA1c ≤ 10% 
T1DM T2DM T1DM T2DM 
8 males 21 males 2 males 31 males 
9 females 14 females 1 females 18 females 
 
5.2 DM as a risk factor for P100 peak time delay 
 
The P100 peak time values were binarized in the moderately controlled DM group (6.5% < 
HbA1c ≤ 10%) and poorly controlled DM (HbA1c > 10%) group using the cut-points for P100 
based on the control group data and defines the threshold for peak time delay measured 
110.64 ms for the right eye as summarised in Table 5.2. 
 
Relative to the moderate control group (6.5% < HbA1c ≤ 10%) the poorly controlled (HbA1c > 
10%) group were not at increased risk for delayed P100 peak time (Right: Odds Ratio = 1,  
ci: 0.454 – 2.204, p = 1.00 ; logistic regression). 
 
Table 5.2: Categorised P100 values by DM group  –Phase 2 – right eye*(N = 52 per group) 
Group (DM) Eye Proportion delayed p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Right 38.5% (20/52) 1.000 
Poor control 
(HbA1c > 10%) 
Right 38.5% (20/52)  
* Fisher’s exact test and p< 0.05. 
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Figure 5.1: Pie graph – P100 peak time by DM group 
 
5.3 DM as a risk factor for N75 peak time delay 
 
Relative to the moderate control group (HbA1c ≤ 10%) the poorly controlled (HbA1c > 10%) 
group were not at increased risk for delayed N75 peak time (Right: Odds Ratio = 0.376,  
ci: 0.0696-2.033, p = 0.256; logistic regression). 
 
Table 5.3: Categorised N75 peak time values by DM group –Phase 2 –right eye*(N = 52 per group) 
Group (DM) Eye Proportion delayed p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Right 9.62% (5/52) 0.437 
Poor control 
(HbA1c > 10%) 
Right 3.85% (2/52)  
* Fisher’s exact test and p< 0.05 
P100 peak time, right eye 
Moderate controlled DM 
(HbA1c ≤ 10 %) 
P100 peak time, right eye 
Poorly controlled DM 
(HbA1c > 10 %) 
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Figure 5.2: Pie graph – N75 peak time by DM group 
 
5.4 DM as a risk factor for N145 peak time delay 
 
Relative to the moderate control group (HbA1c ≤ 10%) the poorly controlled (HbA1c > 10%) 
group were not at increased risk for delayed N145 peak time (Right: Odds Ratio = 1.565,  
ci: 0.415-5.91, p = 0.509; logistic regression). 
 
Table 5.4: Categorised N145 peak time values by DM group – Phase 2 – right eye*(N = 52 per group) 
Group (DM) Eye Proportion delayed p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Right 7.69% (4/52) 0.741 
Poor control 
(HbA1c > 10%) 
Right 11.54% (6/52)  
* Fisher’s exact test and p< 0.05 
N75 peak time, right eye 
Moderate controlled DM 
(HbA1c ≤ 10 %) 
N75 peak time, right eye 
Poorly controlled DM 
(HbA1c > 10 %) 
67 
 
 
 
 
Figure 5.3: Pie graph – N145 peak time by DM group 
 
5.5 DM as a risk factor for amplitude change 
 
Relative to the moderate control group (HbA1c ≤ 10%) the poorly controlled (HbA1c > 10%) 
group were not at increased risk for a change in amplitude (Right: Odds Ratio = 1.151,  
ci: 0.406-3.260, p = 0.791; logistic regression). 
 
Waveform abnormalities of the amplitude measurements are prone to alterations, due to 
participant co-operation, fixation and alertness (ISCEV Guideline 9B, 2008). The amplitude 
value is a reflection of concentration and is not used as an outcome measure due to greater 
inter-individual fluctuations (Regan, 1989).  
 
Poor concentration was grouped as 0 – 5 μV.  
Good concentration was grouped as 5 – 12 μV. 
N145 peak time, right eye 
Moderate controlled DM 
(HbA1c ≤ 10 %) 
N145 peak time, right eye 
Poorly controlled DM 
(HbA1c > 10 %) 
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Table 5.5: Categorised amplitude values by DM group  –Phase 2 –right eye*(N = 52 per group) 
Group (DM) Eye Good 
concentration 
Poor 
concentration 
p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Right 84.62% (44/52) 15.38% (8/52) 1.000 
Poor control 
(HbA1c > 10%) 
Right 82.69% (43/52) 17.31% (9/52)  
* Fisher’s exact test and p< 0.05 
 
 
Figure 5.4: Pie graph – Amplitude by DM group 
 
 
 
 
Amplitude, right eye 
Moderate controlled DM 
(HbA1c ≤ 10 %) 
Amplitude, right eye 
Poorly controlled DM 
(HbA1c > 10 %) 
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5.6 Study group comparisons 
 
The P100 was assessed for this two-factored study design, with the main effects DM group 
(moderate control; poor control) and DM type (T1DM; T2DM) using analysis of covariance 
(ANCOVA) starting with the inclusion of an interaction term and possible covariates age and 
disease durations. 
 
Graphically there was no relationship between P100 and for age of participant, neither for 
disease duration. These parameters as well as the interactions were also not significant in the 
ANCOVA, ie age (p = 0.289), duration of disease (p = 0.836) and interaction (p = 0.758). 
 
Gender was not significantly associated with DM type (p = 0.91) and DM groups (p = 0.76). 
 
The final ANOVA included the main effects only and neither was significant; 
DM groups (p = 0.822; [HbA1c ≤ 10%] 109.59ms vs [HbA1c > 10%] 109.25ms). 
DM type (p = 0.630; [T2DM] 109.59ms vs [T1DM] 108.65ms). 
 
On the continuous scale (original) for P100 peak time, the three groups (control group, 
moderately controlled DM [HbA1c ≤ 10%], poorly controlled DM [HbA1c > 10%]) were 
compared when adjusting for age. The latter approach was adopted due to the generally 
younger age of the control participants (see Figure 5.5). 
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Figure 5.5: Scatter diagram by group for right eye P100 (ms) VS age (years) 
 
5.7 Summary statistics and group comparisons for P100 
 
The P100 measurements of the right eye are summarised by group in Table 5.6. 
 
Table 5.6: Descriptive statistics for P100 peak time in the right eye by group  
Group N 
Mean 
(ms) 
Standard 
deviation (ms) 
Adjusted mean P100 peak time 
(ms) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 109.54 6.38 108.78 
Poor control 
(HbA1c > 10%) 
52 108.94 8.12 109.05 
Control group 30 101.22 3.77 102.33 
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The adjusted means in the last column were derived when groups were compared with 
respect to right eye P100 peak time in a regression analysis which included groups as a main 
factor and age as covariate. The pairwise comparisons between groups, after adjusting for 
age, are given in Table 5.7.  
 
Table 5.7: Group comparisons with respect to P100 peak time in the right eye and adjusted for age 
Comparison Effect (ms) p-value 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control 6.451 0.001 
Poor control (HbA1c > 10%) vs. control 6.719 < 0.001 
Moderate control (6.5% < HbA1c ≤ 10%) vs. poor control 
(HbA1c > 10%) 
-0.268 0.849 
 
Note that, although the two DM groups did not differ (effect: -0.268 ms, p = 0.849), both the 
moderate as well as the poor control groups were significantly delayed compared to the 
control group (HbA1c ≤ 10% effect: 6.45 ms, p = 0.001 and HbA1c > 10% effect: 6.72ms, p < 
0.001). 
 
5.8 Summary statistics N75 
 
The N75 measurements of the right eye are summarised by group and are given in the Table 
5.8. 
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Table 5.8: Descriptive statistics for N75 in the right eye by group  
Group N 
Mean 
(ms) 
Standard 
deviation (ms) 
Adjusted mean N75 peak time 
(ms) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 74.70 8.14 74.57 
Poor control 
(HbA1c > 10%) 
52 72.50 8.10 72.47 
Control group 30 72.80 5.20 72.96 
 
The groups were compared with respect to right eye N75 peak time in a regression analysis 
which included groups as a main factor and age as covariate. The results are given in Table 
5.9. 
 
5.9 N75 – age adjusted peak time results 
 
The two DM groups did not differ from each other (effect: 2.10 ms, p = 0.194) but they also 
were not significantly delayed when compared to the control group (HbA1c ≤ 10%: 1.61 ms, 
p = 0.460 and HbA1c > 10%: 0.48 ms, p = 0.800). 
 
Table 5.9: Group comparisons with respect to N75 in the right eye and adjusted for age 
Comparison Effect (ms) p-value 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control 1.611 0.460 
Poor control (HbA1c > 10%) vs. control 0.484 0.800 
Moderate control (6.5% < HbA1c ≤ 10%) vs. poor control 
(HbA1c > 10%) 
2.095 0.194 
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5.10 Summary statistics N145 
 
The N145 measurements of the right eye are summarised by group and are given in the Table 
5.10. 
 
Table 5.10: Descriptive statistics for N145 in the right eye by group  
Group N 
Mean 
(ms) 
Standard 
deviation (ms) 
Adjusted mean N145 peak time 
(ms) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 142.14 11.36 142.41 
Poor control 
(HbA1c > 10%) 
52 142.70 13.01 142.61 
Control group 30 133.50 9.41 133.10 
 
The groups were compared with respect to right eye N145 peak time in a regression analysis 
which included groups as a main factor and age as covariate. The results are given in Table 
5.11. 
 
5.11 N145 – age adjusted peak time results 
 
Therefore, although the two DM groups did not differ (effect: -0.200 ms, p = 0.936), both the 
moderate as well as the poorly controlled DM groups were significantly delayed when 
compared to the control group (HbA1c ≤ 10%: 9.31 ms, p = 0.006 and HbA1c > 10%: 9.51ms, 
p = 0.001). 
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Table 5.11: Group comparisons with respect to N145 in the right eye and adjusted for age 
Comparison Effect (ms) p-value 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control 9.311 0.006 
Poor control (HbA1c > 10%) vs. control 9.512 0.001 
Moderate control (6.5% < HbA1c ≤ 10%) vs. poor control 
(HbA1c > 10%) 
-0.200 0.936 
 
5.12 Summary statistics amplitude 
 
The amplitude measurements of the right eye are summarised by group and are given in the 
Table 5.12. 
 
Table 5.12: Descriptive statistics for amplitude in the right eye by group  
Group N 
Mean 
(μV) 
Standard 
deviation (μV) 
Adjusted mean amplitude 
(μV) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 10.35 5.01 10.68 
Poor control 
(HbA1c > 10%) 
52 10.01 5.08 9.96 
Control group 30 12.67 5.52 12.19 
 
The groups were compared with respect to right eye amplitude in a regression analysis which 
included groups as a main factor and age as covariate. The results are given in Table 5.13. 
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5.13 Amplitude- measurements as adjusted by age 
 
The two DM groups did not differ significantly (effect: 0.72 μV, p = 0.513) nor did the DM 
group differ significantly from the control group (HbA1c ≤ 10%: -1.51 μV, p = 0.306 and HbA1c 
> 10%: 2.23 μV, p = 0.082). 
 
Table 5.13: Group comparisons with respect to amplitude in the right eye and adjusted for age 
Comparison Effect (μV) p-value* 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control -1.51 0.306 
Poor control (HbA1c > 10%) vs. control 2.23 0.082 
Moderate control (6.5% < HbA1c ≤ 10%) vs. poor control 
(HbA1c > 10%) 
0.72 0.513 
 
5.14 Summary 
 
P100 peak time measurements for both DM groups, moderate control (6.5% < HbA1c ≤ 10%) 
and poorly controlled (HbA1c > 10%), were significantly delayed for the right eye when 
compared to an age adjusted control group (Phase 1).  
 
The next chapter will be the discussion chapter in which the study results are assessed. 
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Chapter Six 
Discussion 
 
The previous chapter dealt with the results of the DM groups. This chapter presents the 
discussion and conclusion of the study. 
 
6.1 Re-visiting purpose and objectives 
 
The purpose of this study was to determine the association between glycated haemoglobin 
levels and P100 pattern-reversal visual evoked potential (PVEP) in diabetes mellitus (DM). To 
achieve the purpose, the following objectives were set: 
 
 to determine whether there is a possible association between the P100 peak time of 
pattern-reversal visual evoked potential (PVEP) and the glycated haemoglobin 
percentage, and 
 to establish whether the central nervous system (CNS), and in particular visual 
function, is affected resulting in DM-related central neuropathy, and whether the type 
of diabetes involved and the duration that the participant has been diagnosed as a 
diabetic. 
 
6.2 Main outcomes 
 
This was an observational cross sectional study conducted in two phases. The participants 
were grouped into Phase 1, the control group, that consisted of 30 non-diabetic participants. 
Phase 2 comprised of 104 diabetic participants of whom 52 had an HbA1c greater than 10% 
and 52 whose HbA1c was 10% and less (moderate diabetic control vs. poor diabetic control). 
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Phase 1 – Control (non-diabetic) group – P100 PVEP results 
 
Determining the P100 peak time measurements for the 30 healthy non-diabetic participants 
was necessary to establish the normative values for this study. The cut-points for the P100 
peak time measurements to determine normal from delayed were determined as the mean 
+2.5 x standard deviations.  
 
The recommended standards for PVEP consider abnormal P100 peak time as 2.5 x standard 
deviations above the mean for a comparable age control sample selected from the normal 
population (ISCEV Guideline 9B, 2008). 
 
The cut-points determining normal from delayed for the P100 peak time in the right eye was 
110.64 ms and 111.86 ms for the left eye. Peak time abnormalities are an indication of visual 
pathway dysfunction once ocular and retinal pathologies have been eliminated as a cause 
upon examination (ISCEV Guideline 9B, 2008). 
 
Phase 2 – Diabetic group – P100 PVEP results 
 
Phase 2 of this study consisted of two diabetic groups. One was a moderately controlled group 
(HbA1c ≤ 10%) and the other a poorly controlled group (HbA1c > 10%).  
The concordance between poorly controlled DM and the increased odds of developing 
polyneuropathy has been established using the HbA1c cut-point of 7% (El-Salem et al., 2009). 
The American Diabetes Association (2010) also advocates for HbA1c levels less than 7%. El-
Salem et al. (2009) further state nerve conduction anomalies in diabetic patients are highly 
correlated to HbA1c levels in the subclinical stages of polyneuropathy. It is for this reason that 
the HbA1c cut-point of 10% was chosen for the poorly controlled diabetic group in this study. 
Moreover, choosing HbA1c < 7% as the cut-point for the current study might have suggested 
that only having early or subtle nerve disease could lead to developing polyneuropathy; thus, 
potentially missing the diagnosis. However, choosing HbA1c levels of 10% and over as the cut-
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point ensured that participants with an advanced disease participated which made the 
comparison between the two DM groups more compelling. 
 
The cut-points for P100 delayed peak time were established in Phase 1 of this study with the 
right eye measuring 110.64 ms; therefore, any measurements above this defined the 
abnormal P100 peak time. 
 
The proportion of delayed P100 peak time for the moderately controlled diabetic group 
(HbA1c ≤ 10%) totalled 38.5% of participants for the right eye. Incidentally, the poorly 
controlled group (HbA1c > 10%) measured their P100 peak time for the right eye at 38.5%. 
The data reflect the poorly controlled (HbA1c > 10%) group did not pose an increased risk for 
delayed P100 peak time relative to the moderately controlled group (HbA1c ≤ 10%). 
 
The visual system encounters functional declines as a result of non-pathological aging. 
Alterations in the retina and its neuro-connections lead to visual decline; VEP helps to 
evaluate these changes to the visual system (Phurailatpam et al., 2014) 
 
Visual evoked potential helps to assess the functional changes of the sensory systems during 
various stages of life (Onofrj et al., 2001). Age must be considered an important factor when 
conducting VEP studies as it has been shown in previous studies that the P100 peak time 
increase with age (Phurailatpam et al., 2014; Onofrj et al., 2001; Emmerson-Hanover et al., 
1994; Celesia et al., 1987; Allison et al., 1984).  
 
The mean age of Phase 1 non-diabetic participants (control group) in this study was 32.6 ± 
8.52 years. In Phase 2 the two diabetic age groups were 56.1 ± 13.04 years for the moderately 
control group (HbA1c ≤ 10%) and 45.2 ± 12.68 years for the poorly controlled group (HbA1c > 
10%). Because age is an important variable in the measurement of P100 peak time, and in this 
study the average age for the control group was younger than that of the two diabetic groups, 
regression analysis was employed among the three groups as a main factor and age was a 
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covariate. The adjusted mean age for the comparison of P100 peak time measurements 
among the three groups was 46.64 years. 
 
The results of the P100 measurements in this study indicated the measurements of the two 
DM groups did not differ significantly: the moderately controlled group (HbA1c ≤ 10%) 
measured 108.78 ms and the poorly controlled group (HbA1c > 10%) measured 109.05 ms; 
thus, the effect was (-0.268 ms, p = 0.849) between the two DM groups. These two DM groups 
were, however, significantly delayed compared to that of the control group (HbA1c ≤ 10%: 
6.4 ms, p = 0.001 and HbA1c > 10%: 6.72 ms, p < 0.001). 
 
The primary objective of this study was to establish whether an association existed between 
the P100 peak time measurements and the glycated haemoglobin percentage when 
comparing two diabetic groups (a moderately controlled group [HbA1c ≤ 10%] with a poorly 
controlled group [HbA1c > 10%]) by using cut-points obtained from a non-diabetic control 
group.  
 
The results reflect that diabetic control has no connection in increasing the P100 peak time 
measurements because the moderately control group (HbA1c ≤ 10%) presented results nearly 
identical to that of the poorly controlled group (HbA1c > 10%) for P100 measurements in the 
right eye. The proportion of delayed P100 measurements of the participants’ right eyes was 
38.5% for both DM groups. 
 
Conversely, the P100 results of Phase 2, the DM group, reflect a significant delay (p<0.001) 
when compared to the non-diabetic control group in Phase 1 of the study. This result 
correlates with the finding of Heravian et al. (2012) in that 40% of their diabetic participants 
without retinopathy presented with P100 peak time above the normal range cut-points. 
Heravian et al. (2012) did not appreciate any correlation with P100 abnormalities and 
glycemic control. Algan et al. (1989) found 28% of their DM participants showed a significantly 
delayed P100 in comparison with their control group with no correlation to metabolic control. 
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The secondary objective of this study was to establish whether the type of DM involved and 
the duration since the participants’ diagnoses as diabetics had an effect on the P100 
measurements, and if this was the case, whether it affected the central nervous system (CNS), 
particularly the visual function. The Phase 1 control group was not included in this section. A 
two-way ANOVA was carried out on the DM group and no effect was found between DM 
types (p = 0.630) (T1DM and T2DM) or between DM groups (p = 0.822) (HbA1c > 10% and 
HbA1c ≤ 10%); hence, no interaction was observed between DM groups and DM types. 
 
It was also observed in the results of this study that the duration of DM had no influence on 
the P100 peak time measurements(p = 0.836). Ismail (2014), Hervian et al. (2012), Ziegler et 
al. (1994) and Algan et al. (1989) indicated results similar to these of the present study in that 
the participants in their studies showed no correlation between P100 peak time and the type 
or duration of DM. On the other hand, in various other studies conducted by authors such as 
Kumar et al. (2014), Shrivastava et al. (2014), Bhanu et al. (2012), Chopra et al. (2011), Dolu 
et al. (2003) and Azal et al. (1998) it was found a significant positive correlation existed 
between the duration of DM and the P100 peak time. 
 
There was no sign of decreased visual function in the participants in this study. Specifically, 
the DM group did not reflect any sign of decreased visual function or, more particularly, an 
exaggerated P100 peak time such as evidenced in an optic neuropathy pathology. 
 
6.3 Limitations 
 
The study did not present with too many unforeseen difficulties. Some minor problems were 
encountered, such as the time factor. The time factor for recruiting the poorly controlled 
diabetic group participants (HbA1c > 10%) took longer than expected. Another challenge was 
that some of the diabetic participants then did not qualify for enrolment in the study due to 
having ocular pathology such as cataracts or diabetic retinopathy (all ocular pathology was 
excluded by the study protocol as mentioned in Chapter 3).  
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These study limitations were however unrelated to any equipment or system failure. 
 
Seven participants from the moderately controlled group (HbA1c ≤ 10%) were found to be 
unsuitable participants due to ocular pathology in the form of cataracts. No other diabetic 
related ocular pathology was detected in this group of participants and all 52 participants met 
the study inclusion requirements. 
 
Eight participants from the poorly controlled group (HbA1c > 10%) were found to be 
unsuitable participants due to ocular pathology in the form of cataracts and diabetic 
retinopathy. Two participants presented with cataracts and six participants presented with 
diabetic retinopathy. Four participants presented with moderate non-proliferative diabetic 
retinopathy and two with mild non-proliferative retinopathy. The necessary ophthalmological 
referrals were all made for those participants who presented with ocular pathology. All 52 
participants met the study inclusion requirements. 
 
The average age of the moderately controlled group (HbA1c ≤ 10%) was 56.1 ± 13.04 years. 
This group consisted of 33 male and 19 female participants. The average age for the poor 
control group (HbA1c > 10%) was 45.2 ± 12.68 years with 29 male and 23 female participants. 
It was to be expected that cataract formation would be present in this age group (Jeganathan 
et al., 2008). The duration of each participant being diagnosed as a diabetic in years was 
similar in both groups, namely, HbA1c ≤ 10%: 7.8 ± 5.9 and HbA1c > 10%: 9.1 ± 6.3. This factor 
would also have contributed to cataract development.  
 
The mean age of the control group (non-diabetics) was 32.6 ± 8.52 years whereas the mean 
age for the poorly controlled group (HbA1c > 10%) was 45.2 ± 12.68 years. For the moderately 
controlled group (HbA1c ≤ 10%) the mean age was 56.1 ± 13.04 years. The differences in the 
mean age resulted in a non-aged matched comparison which necessitated using regression 
analysis among the three groups as a main factor and age a covariate. 
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The study design of having one referral source for all the participants of this study was a 
private medical specialist physician practice, and therefore the amount of diabetic 
participants may have been limited. Having a larger diabetic participant referral source , such 
as a dedicated diabetic clinic may have made the recruitment process of all the participants 
easier as well as potentially having a better age match for the control group (non-diabetic 
group) and the two diabetic groups used in this study. 
 
6.4 Confounding variables 
 
The study results of Phase 1 did not produce any confounding results, but there was a slight 
difference between the right eye and left eye of the P100 ICC repeatability measurements 
(0.928 and 0.831 respectively). A possible explanation for this could be participant fatigue as 
the study protocol was to always start with the right eye first. However, these ICC results are 
still repeatable and therefore reliable.  
 
The Phase 2 study results produced identical results for the right eye P100, whereby 38.5% of 
the participants produced a delayed P100 peak time of p = 1.00 for both the HbA1c ≤ 10% and 
the HbA1c > 10% groups.  
 
6.5 Improvements and future work 
 
The results of this study clearly demonstrate a proof of concept that DM has an influence on 
the optic nerve conduction and on all levels of control; thus, an effect on the CNS. A large 
randomised trial is needed to explore this concept further whereby other components of the 
optic nerve need to be measured and the physiology of the optic nerve be assessed to 
determine whether the P100 peak time delays are episodes of exacerbations or whether it is 
a stable peak time delay. 
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Randomised trials have long been considered as the gold standard when it comes to clinical 
research (Akobeng, 2005), and this trial could take place in a diabetic department of a medical 
training hospital, having an ophthalmic as well as a neurophysiological departments. 
 
6.6 Discussion 
 
Peripheral neuropathy is one of the first complications to arise in DM. This is possibly due to 
damaging of the small diameter nerve fibres which consist of 70 – 90% of all the peripheral 
nerve fibres (Smith & Singleton, 2008). Neuropathic pain results from injury to the small-fibre 
nerves and this is one of the most disabling symptoms of diabetic neuropathy (Gandhi et al., 
2010). The Oslo study was a long-term follow-up study examining T1DM of long duration. 
Large- and small-nerve fibre function and their association with HbA1c were investigated. The 
Oslo study investigators emphasise the importance of having good glycaemic control, 
especially for long-term T1DM, to preserve large- and small-fibre function because it plays a 
vital role in neuropathy development. In the Oslo study it was concluded that HbA1c is a 
significant risk factor associated with the progression of large- and small-fibre damage in long-
term T1DM (Sveen et al., 2013). 
 
The Diabetes Control and Complications Trial (DCCT) research group demonstrated a clear 
link between glycaemia and the advancement of microvascular complications in T1DM where 
the HbA1c measures 6 – 11% after a period of six years (DCCT, 1996). 
 
In their study on T2DM, Stratton et al. (2000) observed a highly significant link between the 
advancement of diabetes-related complications with hyperglycaemia as measured with the 
mean HbA1c in the reference range of < 6 HbA1c > 10%. These researchers furthermore 
found a 1% reduction in HbA1c reduced the risk for microvascular complications by 37% as 
well as having a 21% lower risk of death related to diabetes.  
 
A secondary aim of this study was to investigate the possible effect of DM and its effects on 
the central nervous system (CNS), in particular the effects on visual function. 
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Nonarteritic anterior ischaemic optic neuropathy (NAION) is the most prevalent acute optic 
neuropathy in individuals aged 50 years and older (Hattenhauer et al., 1997). The aetiology 
of NAION is multifactorial; however, vascularpathic disorders such as DM are frequently cited 
as a risk factor (Jacobson et al., 1997). 
 
A systematic review and meta-analysis was undertaken by Chen et al. (2013) to investigate 
the associated increased risk of NAION and DM. The conclusion of Chen et al. (2013) was that, 
according to their meta-analysis, DM increases the risk of NAION (OR = 1.64; 95% CI = 1.17 – 
2.30; p = 0.004). These authors state the proper control of blood glucose levels could reduce 
the risk of developing NAION; they stress the importance of neuro-ophthalmic investigations 
that focus on diabetics who have visual symptoms indicative of NAION.  
 
The findings of Chen et al. (2013) concur with those of Lee et al. (2011) who used a large study 
sample of 25 515 diabetics and an equal number of age- and gender-matched non-diabetics 
to determine the development of the incidence of NAION among DM patients and among the 
elderly. The study results of Lee et al. (2011) indicate a significantly increased risk of NAION 
in DM. 
 
Visual evoked potential (VEP) is a non-invasive instrument used to examine the activity of the 
visual system. The effect of nerve conduction change can be assessed by noting the peak time 
delay of the VEPs (Jones & Brusa, 2003). The P100 peak time prolongation represents the size 
of the demyelinated optic nerve fibres; therefore, VEP provides a highly sensitive instrument 
to measure demyelination of the optic nerve (You et al., 2011). 
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Chapter Seven 
Conclusions 
 
The results of the present study are significant in terms of the clinical relevance of measuring 
the PVEP P100 peak time in people having DM of all classifications and control. The proportion 
of P100 delayed peak time of 38.5% for both DM groups may lead to further questions and 
studies researching whether the optic nerve as a component of the CNS has a greater form of 
protection against damage resulting from hyperglycaemia. Ewing et al. (1985) found that in 
DM the CNS cells were less afflicted than the PNS cells. They ascribe this finding to the 
possibility that, due to the blood-brain barrier, transport for glucose decreases in the CNS and 
the levels of glycation products are lower in the CNS compared to its level in the peripheral 
nerves. 
 
This study revealed that the P100 PVEP peak time is indeed associated with the HbA1c 
measurements of diabetics. Whether poorly controlled or moderately controlled DM, 
demyelination of the CNS occurs in 38.5% of cases. In adition, the use of PVEP in DM is a useful 
non-invasive procedure to detect retinal dysfunction at the ganglion cell level, and can thus 
be considered as preclinical diabetic retinopathy screening, therefore PVEP in DM has the 
potential to reduce DM complications. 
 
The important question to ask is in how many diabetic clinics is the physiology of the optic 
nerve examined. DM is a chronic lifestyle disease with far-reaching implications for millions 
of people who suffer from it as well as being a condition which can lead to both acute and 
chronic complications and even death. With the looming possibility that the already 
excessively high global number of people living with DM may increase to 592 million by the 
year 2035, diabetic clinics need to include an examination of the physiology of the optic nerve 
in DM patients; DM patients need to be examined from foot to eye to prevent complications 
and improve their condition.  
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Appendix A - Research Ethics Board Approval  
 
The study was approved by the Aston University Ethical Committee on 10th April 2013. 
(Ethics application number 421). 
 
The primary ethical issues raised by the design of this protocol are the recordings of the 
visual evoked potentials of two groups of diabetic participants. 
 
It is necessary to put the following additional precautions for the research participants in 
place. 
 
Anonymity 
 
This will be preserved by the removal of particiants’ identities and not using their personal 
identification (ID) numbers. A coding system will be introduced and each participant will be 
allocated a specific code(a number 1-134) which can be linked back to Prof. Ker’soriginal 
record cardof the participant, should cross-referencing be needed when writing up of the 
study. 
 
Risks and Benefits 
 
There is no apparent foreseen risks to the study participants. Apart from applanation 
tonometry and the placing of the electrodes to the subject’s head which some may or may 
not exprience as a little uncomfortable, all other tests are non-invasive. Should a mydriatic 
agent be needed 0.5% tropicamide will be instilled only after the necessary precautions 
have been carried out to ensure the safe installation of the dilating drops. Apart from minor 
stinging and the cycloplegia for six hours there will be no other posssible risk to the 
participants. 
99 
 
 
 
On the other hand, the participants may benefit from this study in that they will be made 
aware of whether there is any damage to their optic nerves as measured by their P100 
wavelengths. 
 
Informed Consent 
 
After the purpose and study method have been explained to every individual participant 
they will be given the opportunity to decide whether they want to participate or not. From 
those who voluntarily decide to participate verbal and signed written consent will be 
obtained. Additional protection of the research participant is the informed consent giving 
Mr MD Nagle access to Prof. Ker’s clinical record card of every participant. 
 
Voluntary Participation 
 
Participation will be voluntary. No partipants will be pressurised or coerced to participate in 
this study. No remuneration for participation will be offered or accepted. The participants 
will be assured that they can decide to withdraw from the study at any time without stating 
a reason and without prejudice. 
 
Privacy and Confidentiality 
 
Prof. Ker will be recruiting the participants from clients in his private practice. A file number 
will be allocated to every participant and will be used as his or her code number throughout 
the study process. Also, the presentation of the results of the study will omit names or any 
other information that can link the participant to the study. The possibility that a participant 
can be identified or that she or he can be linked to the data is not negotiable and therefore 
the participants’ confidentiality and anonymity will be maintained and guaranteed at all 
times during and after the study has been completed. 
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The research data will be analysed by both Prof. Ker and Mr Nagle. Prof. Ker willhave the 
responsibility to keep all the data and images captured confidential. 
 
By instituting these additional protections, the risks have been appropriately minimised and 
a reasonable and ethically acceptable balance between risks and benefits has been 
established. 
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Appendix A2 – Pharma-Ethics 
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Appendix B – Sample Consent Form 
Mark Nagle-Student number: 109089665  
Consent form:  
Research workers, school and subject area responsible:  
 Professor James Ker- Specialist Physician/ Cardiologist, Department of Internal 
Medicine, University of Pretoria, South Africa.  
 Mr. Mark Nagle- Optometrist, Life and Health Sciences, Vision Sciences, Aston 
University, United  
Kingdom.  
Project Title:  
The association between glycated haemoglobin levels and P100 visual evoked potentials in 
diabetes mellitus. 
 Invitation:  Phase 1 of the study 
You are being invited to take part in a research study. Before you decide it is important for 
you to  
understand why the research is being done and what it will involve. Please take time to read 
the  
following information carefully.  
What is the purpose of the study?  
The purpose of this study is to monitor the changes in diabetes mellitus that take place within 
the  
central nervous system, particularly its relationship to vision. Visual evoked potentials are 
used as a simple, sensitive test that allows one to investigate the central nervous system 
without needing any input from the participant. The test is able to detect early changes to the 
nerves before any symptoms arise. There are no direct benefits by taking part in this study, 
apart from gaining the knowledge of how diabetes affects the visual system.  
 
Why have I been chosen?  
You have been chosen to participate in our study, as part of our control group.  The results 
from the control group will be compared with the results from two groups of diabetic 
participants. One group will have glycated haemoglobin percentage values that are equal to 
or greater than 10 %. The other group will have glycated haemoglobin percentage values that 
are less than 10 %. Certain people will not be able to take part in the study, and these include 
those with existing ocular pathology, namely cataracts or any other media opacity or optic 
nerve disease or any retinal pathology. 
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What will happen to me if I take part? 
By volunteering to be a participant in our study you will have a comprehensive eye 
examination, 
including photography of the back of your eye. This is in order to exclude any ocular pathology  
which could influence the results of our study.  
 
The study itself will be completed in one visit, except if pupil dilation is required, then a second 
visit will be required. You will be asked to observe a black and white alternating checker board 
pattern in a semi-dark room. Three electrodes will be carefully placed on your head; these 
electrodes are commonly used in medical environments and will not cause any pain or 
discomfort. They are used to measure signals from your central nervous system. 
 
All you will be asked to do is to pay close attention to the video monitor at all times. This test 
will take no longer than 15 minutes, and together with the comprehensive eye examination 
the total visit time should be no more than one hour. 
 
Are there any potential risks in taking part in the study?  
The risks in participating in the study are minimal as all tests are used in the course of clinical 
practice.  
The use of eye drops may result in minor stinging that could last for up to 15 seconds. The 
effects of the dilating eye drops could result in your eyes being extra light sensitive and not 
able to focus comfortably for six hours after installation, and this may affect your ability to 
drive or to operate heavy machinery. Therefore, it is recommended that you do not do either 
of these activities for at least six hours from the installation of the dilating eye drops.  
 
Very rarely, patients experience more severe side effects from the eye drops. However the 
investigator will monitor you closely following instillation of the drops to ensure that any 
treatment that might be required is administered appropriately. 
 
It would be helpful if you did not apply any hair spray or other hair products on the day of 
the study, as this could make placement of the electrodes more difficult. 
 
Do I have to take part?  
No, you do not have to participate if you do not wish to do so. You are free to withdraw from 
the study at any time. The researchers may suggest that you withdraw from the study if they 
consider it appropriate.   
 
Expenses and payments:  
There are no expenses or payments for participation in this study.  
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Will my taking part in this study be kept confidential?  
Privacy and confidentiality will be protected vigorously to the extent permissible by law. All 
data in written form as well as electronic form will be kept by Prof J Ker, along with your 
original clinical records held by this practice. All the necessary information obtained by your 
participation in this study will be in anonymous form. Prof Ker will allocate a code to your 
research file, and this code can be used by him to link back to your clinical records held by 
him. All your records pertaining to this study will be kept for a minimum of 15 years, 
thereafter all data would be disposed of in accordance to the data protection act of the GOC. 
We cannot, however, guarantee privacy or confidentiality.  
 
What will happen to the results of the research study?  
The results of the study would be used in order to complete the doctorate degree of Mr M.D 
Nagle. We also aim to publish the results of this study. However, there will be no reference 
to any individual’s performance in any publication. The results of the study can be obtained 
directly from Prof J Ker, however each participant will be given a full explanation of their 
results.   
 
Who is organizing and funding the research?  
Mr M.D Nagle is organizing the study, however there is no external funding for this research 
project. 
 
Who has reviewed the study?  
The study has been reviewed by the Aston University Research Ethics Committee. 
 
Who do I contact if something goes wrong or I need further information?  
Please feel free to contact Prof James Ker (jker@wol.co.za), +2712 341 0078  
 
Who do I contact if I wish to make a complaint about the way in which the  
research is conducted?  
If you have any concerns about the way in which the study has been conducted, then you 
should contact the Secretary of the University Research Ethics Committee on 
j.gwalter@aston.ac.uk or telephone 0121 204 4665.  
Volunteer consent form  
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Title of project:The association between glycated haemoglobin levels and P100 visual 
evoked potentials in diabetes mellitus. 
 
Name of Chief Researcher: Prof James Ker  
  Initial 
1 I confirm that I have read and understand the information sheet for the 
above  
study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.  
 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.   
 
3 Should it be necessary, I give consent for Mr MD Nagle to view my clinical 
records held by Prof J ker.   
 
4 I agree to take part in the above study.  
 
Name of 
participant 
 
 
 Name of 
researcher 
 
 
Date 
 
 Date  
Signature 
 
 
 Signature  
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Mark Nagle-Student number: 109089665  
Consent form:  
Research workers, school and subject area responsible:  
 Professor James Ker- Specialist Physician/ Cardiologist, Department of Internal 
Medicine, University of Pretoria, South Africa.  
 Mr. Mark Nagle- Optometrist, Life and Health Sciences, Vision Sciences, Aston 
University, United  
Kingdom.  
Project Title:  
The association between glycated haemoglobin levels and P100 visual evoked potentials in 
diabetes mellitus. 
 Invitation: Phase 2 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully.  
 
What is the purpose of the study? The purpose of this study is to monitor the changes in 
diabetes mellitus that take place within the central nervous system, particularly its 
relationship to vision. Visual evoked potentials are used as a simple, sensitive test that allows 
one to investigate the central nervous system without needing any input from the participant. 
The test is able to detect early changes to the nerves, before any symptoms arise. There are 
no direct benefits by taking part in this study, apart from gaining the knowledge of how 
diabetes affects the visual system.  
Why have I been chosen? You have been chosen to participate in our study, as your 
glycatedhemoglobin percentage meets the requirement criteria of our study. One hundred 
and four participants are needed for the successful completion of the study. The participants 
will be grouped into two groups of fifty two each, those who’s HbA1c is greater or equal to 
10%, and those that are below 10%. Certain people will not be able to take part in the study, 
and these include those with diabetic retinopathy, or existing ocular pathology, including 
cataracts, optic nerve disease or any retinal pathology. 
What will happen to me if I take part?By volunteering to be a participant in our study you 
will have a comprehensive eye examination, including photography of the back of your eye. 
This is in order to exclude any ocular pathology which could influence the results of our study.  
The study itself will be completed in one visit, except if pupil dilation is required, then a second 
visit will be required. You will be asked to observe a black and white alternating checker board 
pattern in a semi-dark room. Three electrodes will be carefully placed on your head; these 
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electrodes are commonly used in medical environments and will not cause any pain or 
discomfort. They are used to measure signals from your central nervous system.  
 
All you will be asked to do is to pay close attention to the video monitor at all times. This test 
will take no longer than 15 minutes, and together with the comprehensive eye examination 
the total visit time should be no more than one hour. 
 
Are there any potential risks in taking part in the study? The risks in participating in the study 
are minimal as all tests are used in the course of clinical practice. The use of eye drops may 
result in minor stinging that could last for up to 15 seconds. The effects of the dilating eye 
drops could result in your eyes being extra light sensitive and not able to focus comfortably 
for six hours after installation, and this may affect your ability to drive or to operate heavy 
machinery. Therefore, it is recommended that you do not do either of these activities for at 
least six hours from the installation of the dilating eye drops. 
 
 Very rarely, patients experience more severe side effects from the eye drops. However the 
investigator will monitor you closely following instillation of the drops to ensure that any 
treatment that might be required is administered appropriately.  
 
It would be helpful if you did not apply any hair spray or other hair products on the day of the 
study, as this could make placement of the electrodes more difficult.  
 
Do I have to take part? No, you do not have to participate if you do not wish to do so. You 
are free to withdraw from the study at any time. The researchers may suggest that you 
withdraw from the study if they consider it appropriate.  
Expenses and payments: There are no expenses or payments for participation in this study.  
Will my taking part in this study be kept confidential? Privacy and confidentiality will be 
protected vigorously to the extent permissible by law. All data in written form as well as 
electronic form will be kept by Prof J Ker, along with your original clinical records held by this 
practice. All the necessary information obtained by your participation in this study will be in 
anonymous form. Prof Ker will allocate a code to your research file, and this code can be used 
by him to link back to your clinical records held by him. All your records pertaining to this 
study will be kept for a minimum of 15 years, thereafter all data would be disposed of in 
accordance to the data protection act of the GOC. We cannot, however, guarantee privacy or 
confidentiality.  
What will happen to the results of the research study? The results of the study would be 
used in order to complete the doctorate degree of Mr M.D Nagle. We also aim to publish the 
results of this study. However, there will be no reference to any individual’s performance in 
any publication. The results of the study can be obtained directly from Prof J Ker, however 
each participant will be given a full explanation of their results.   
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Who is organizing and funding the research? Mr M.D Nagle is organizing the study, however 
there is no external funding for this research project. 
Who has reviewed the study? The study has been reviewed by the Aston University Research 
Ethics Committee 
Who do I contact if something goes wrong or I need further information? Please feel free to 
contact Prof James Ker (jker@wol.co.za), +2712 341 0078  
Who do I contact if I wish to make a complaint about the way in which the research is 
conducted? If you have any concerns about the way in which the study has been conducted, 
then you should contact the Secretary of the University Research Ethics Committee on 
j.gwalter@aston.ac.uk or telephone 0121 204 4665.  
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Volunteer consent form  
Title of project:The association between glycated haemoglobin levels and P100 visual 
evoked potentials in diabetes mellitus. 
Name of Chief Researcher: Prof James Ker  
  Initial 
1 I confirm that I have read and understand the information sheet for the 
above  
study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.  
 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.   
 
3 Should it be necessary, I give consent for Mr MD Nagle to view my clinical 
records held by Prof J Ker.   
 
4 I agree to take part in the above study.  
 
Name of 
participant 
 
 
 Name of 
researcher 
 
 
Date 
 
 Date  
Signature 
 
 
 Signature  
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Appendix C 
Data Analysis for Left Eye 
Phase 2 DM Group 
 
1 Phase 2 – Diabetic group analysis 
 
The results for this group are represented by data of the left eye only.  
 
The moderately controlled DM group (6.5% < HbA1c ≤ 10%) consisted of 52 participants; 33 
males and 19 females. The mean age for this group was 56.1 ± 13.04 years and the mean 
duration in years for this group was 7.8 ± 5.9 years. The poorly controlled DM group (HbA1c 
> 10%) comprised of 52 participants: 29 males and 23 females. The mean age for this group 
was 45.2 ± 12.68 years and the mean duration in years for this group was 9.1 ± 6.3 years. DM 
group (moderate;poor) differed significantly with respect to age (Student’s two-sample t-test: 
p< 0.001) but not with respect to disease duration (Student’s two-sample t-test: p = 0.294).  
Furthermore the DM groups also did not differ with respect to gender distribution (Fisher’s 
exact test: p = 0.549 Males: 63.5% (33/52) vs 55.8% (29/52)or Females: 36.5% (19/52) vs 44.2% 
(23/52)). 
 
The P100 peak time values were categorised in the moderately controlled DM group (6.5% < 
HbA1c ≤ 10%) and poorly controlled DM (HbA1c > 10%) group using the cut-points for P100 
based on the control group and defines the threshold for peak time delay measured 111.86 
ms for the left eye as summarised in the Table 1. 
 
2. DM as a risk factor for P100 peak time delay 
 
Relative to the moderate control group (6.5% < HbA1c ≤ 10%) the poorly controlled (HbA1c > 
10%) group were not at increased risk for delayed P100 peak time (Left: Odds Ratio = 0.722, 
ci 0.327 – 1.596, p = 0.421). 
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Table 1: Categorized P100 values by DM group - Phase 2 –left eye*(N = 52 per group) 
Group (DM) Eye Proportion delayed p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Left 42.3% (22/52) 0.546 
Poor control 
(HbA1c > 10%) 
Left 34.6% (18/52)  
* Fisher’s exact test and p < 0.05. 
 
3. DM as a risk factor for N75 peak time delay 
 
Relative to the moderate control group (6.5% < HbA1c ≤ 10%) the poorly controlled (HbA1c > 
10%) group were not at increased risk for delayed N75 peak time (Left: Odds Ratio= 0.698,  
ci: 0.266-1.832, p = 0.465; logistic regression). 
 
Table 2: Categorized N75 peak time values by DM group - Phase 2 –left eye*(N = 52 per group) 
Group (DM) Eye Proportion delayed p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Left 23.08% (12/52) 0.626 
Poor control 
(HbA1c > 10%) 
Left 17.31% (9/52)  
 
4. DM as a risk factor for N145 peak time delay 
 
Relative to the moderate control group (6.5% < HbA1c ≤ 10%)the poorly controlled (HbA1c > 
10%) group were not at increased risk for delayed N145 peak time (Left: Odds Ratio= 2.130,  
ci: 0.503-9.02, p =0.304; logistic regression). 
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Table 3: Categorized N145 peak time values by DM group - Phase 2 –left eye*(N = 52 per group) 
Group (DM) Eye Proportion delayed p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Left 5.77% (3/52) 0.488 
Poor control 
(HbA1c > 10%) 
Left 11.54% (6/52)  
* Fisher’s exact test and p < 0.05. 
 
5. DM as a risk factor for amplitude change 
 
Relative to the moderate control group (6.5% < HbA1c ≤ 10%)the poorly controlled (HbA1c > 
10%) group were not at increased risk for a change in amplitude (Left: Odds Ratio= 1.725,  
ci: 0.611-4.870, p =0.303; logistic regression). 
 
Waveform abnormalities of the amplitude measurements are prone to alterations, due to 
participant co-operation, fixation and alertness (ISCEV Guideline 9B, 2008). The amplitude 
value is a reflection of concentration and is not used as an outcome measure due to greater 
inter-individual fluctuations (Regan, 1989).  
 
Poor concentration was grouped as 0-5 μV 
Good concentration was grouped as 5-12 μV 
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6. Study group comparisions 
 
The P100 was assessed for this two-factored study design, with the main effects DM group 
(moderate;poor) and DM type (T1DM; T2DM) using analysis of variance (ANCOVA) starting 
with the inclusion of an interaction term and possible covariates age and disease durations. 
 
Graphically there was no relationship between P100 and either of age and disease durations 
and these parameters as well as the interactions were also not significant in the ANCOVA, ie 
age (p = 0.212), duration of disease (p = 0.961) and interaction (p = 0.763). 
 
The final ANOVA included the main effects only and neither was significant; 
DM groups (p = 0.402; [HbA1c ≤ 10%] 110.31ms vs [HbA1c > 10%] 109.03ms). 
DM type (p = 0.904; [T2DM] 110.31ms vs [T1DM] 110.54ms). 
 
Table 4: Categorized Amplitude values by DM group - Phase 2 –left eye*(N = 52 per group) 
Group (DM) Eye Good 
concentration 
Poor 
concentration 
p-value* 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
Left 86.54% (45/52) 13.46% (7/52) 0.438 
Poor control 
(HbA1c > 10%) 
Left 78.85 (41/52) 21.15% (11/52)  
* Fisher’s exact test and p < 0.05. 
 
7. Summary statistics P100 
 
The P100 measurements of the left eye are summarised by group and are given in the Table 
5. 
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Table 5: Descriptive statistics for P100 peak time in the left eye by group  
Group N 
Mean 
(ms) 
Standard 
Deviation (ms) 
Adjusted mean P100 peak time 
(ms) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 110.32 6.10 109.68 
Poor control 
(HbA1c > 10%) 
52 109.11 8.30 109.20 
Control group 30 101.00 4.35 102.00 
 
The groups were compared with respect to left eye P100 peak time in a regression analysis 
which included groups as a main factor and age as covariate. The results are given in the Table 
6. 
 
8. P100 – age adjusted peak time results 
 
The two DM groups did not differ significantly (effect: 0.47ms, p = 0.738), however both 
moderate and poorly controlled were significantly delayed compared to the control group 
(HbA1c ≤ 10%: 7.73ms, p < 0.001 and HbA1c > 10%: 7.25ms, p < 0.001). 
 
Table 6 Group comparisons with respect to P100 peak time in the left eye and adjusted for age 
Comparison Effect (ms) p-value* 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control 7.730 <0.001 
Poor control (HbA1c > 10%) vs. control 7.254 <0.001 
Moderate control (6.5% < HbA1c ≤ 10%) vs. Poor control 
(HbA1c > 10%) 
0.473 0.738 
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9. Summary statistics N75 
 
The N75 measurements of the left eye are summarised by group and are given in the Table 7. 
 
Table 7 Descriptive statistics for N75 in the left eye by group  
Group N Mean 
(ms) 
Standard 
Deviation (ms) 
Adjusted mean N75 peak time 
(ms) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 76.32 8.10 75.90 
Poor control 
(HbA1c > 10%) 
52 73.11 9.45 73.18 
Control group 28 71.44 3.30 71.95 
 
The groups were compared with respect to left eye N75 peak time in a regression analysis 
which included groups as a main factor and age as covariate. The results are given in the  
Table 8.  
 
10. N75 – age adjusted peak time results 
The two DM groups differed from each other by (effect: 2.84ms, p = 0.96), they were not 
significantly delayed when compared to the control group (HbA1c ≤ 10%: 2.84ms, p = 0.089 
and HbA1c > 10%: -1.21ms, p = 0.552). 
 
Table 8: Group comparisons with respect to N75 in the left eye and adjusted for age 
Comparison Effect (ms) p-value* 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control 2.84 0.089 
Poor control (HbA1c > 10%) vs. control -1.21 0.552 
Moderate control (6.5% < HbA1c ≤ 10%) vs. Poor control 
(HbA1c > 10%) 
2.84 0.096 
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11. Summary statistics N145 
 
The N145 measurements of the left eye are summarised by group and are given in the  
Table 9. 
 
Table 9: Descriptive statistics for N145 in the left eye by group  
Group N 
Mean 
(ms) 
Standard 
Deviation (ms) 
Adjusted mean N145 peak time 
(ms) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 143.57 11.33 144.03 
Poor control 
(HbA1c > 10%) 
52 143.45 13.61 143.38 
Control group 30 132.54 10.57 131.87 
 
The groups were compared with respect to left eye N145 peak time in a regression analysis 
which included groups as a main factor and age as covariate. The results are given in  
Table 10. 
 
12. N145 – age adjusted peak time results 
 
Thus although the two DM groups did not differ (effect: 0.650ms, p = 0.802), both moderate 
as well as the poorly controlled DM groups were significantly delayed when compared to the 
control group (HbA1c ≤ 10%: 12.16ms, p = 0.001 and HbA1c > 10%: 11.51ms, p < 0.001). 
 
  
119 
 
 
 
Table 10: Group comparisons with respect to N145 in the left eye and adjusted for age 
Comparison Effect (ms) p-value* 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control 12.160 0.001 
Poor control (HbA1c > 10%) vs. control 11.513 < 0.001 
Moderate control (6.5% < HbA1c ≤ 10%) vs. Poor control 
(HbA1c > 10%) 
0.650 0.802 
 
13. Summary statistics amplitude 
 
The amplitude measurements of the left eye are summarised by group and are given in the 
Table 11. 
 
Table 11: Descriptive statistics for amplitude in the left eye by group 
Group N 
Mean 
(μV) 
Standard 
Deviation (μV) 
Adjusted mean amplitude 
(μV) when age is 46.64 years 
Moderate control 
(6.5% < HbA1c ≤ 10%) 
52 9.87 4.43 9.88 
Poor control 
(HbA1c > 10%) 
52 9.57 4.80 9.57 
Control group 30 12.28 5.33 12.27 
 
The groups were compared with respect to left eye amplitude in a regression analysis which 
included groups as a main factor and age as covariate. The results are given in Table 12. 
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13. Amplitude – measurements as adjusted by age 
 
The two DM groups did not differ significantly (effect: 0.307 μV, p = 0.803) compared to each 
other, however the poorly controlled DM group (HbA1c > 10%) was significantly different 
from the control group, but this was not so for the moderate DM group (HbA1c ≤ 10%: -2.40 
μV, p = 0.103 and HbA1c > 10%: 2.70 μV, p = 0.024). 
 
Table 12: Group comparisons with respect to amplitude in the left eye and adjusted for age 
Comparison Effect (μV) p-value* 
Moderate control (6.5% < HbA1c ≤ 10%) vs. control -2.402 0.103 
Poor control (HbA1c > 10%) vs. control 2.700 0.024 
Moderate control (6.5% < HbA1c ≤ 10%) vs. Poor control 
(HbA1c > 10%) 
0.307 0.803 
 
14. Summary  
 
P100 peak time measurements for both DM groups, moderate control (6.5% < HbA1c ≤ 10%) 
and poorly controlled (HbA1c > 10%), were significantly delayed for the left eye when 
compared to an age adjusted control group (Phase 1).  
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Appendix D 
Raw Data 
Data table for Control Participants-Phase 1  
              
NO GENDER AGE HbA1c R EYE 
N75 
(ms) 
P100 
(ms) 
N145 
(ms) 
AMP 
(uV) L EYE 
N75 
(ms) 
P100 
(ms) 
N145 
(ms) 
AMP 
(uV) 
1 MALE 39 5.30% R EYE 
          
85.2  
        
104.7  
        
119.4  
            
9.3   L EYE  
          
75.6  
        
104.7  
        
122.1  
            
8.1  
2 MALE 34 5.40% R EYE 
          
75.9  
          
98.7  
        
146.4  
            
4.7   L EYE  
          
75.9  
          
98.7  
        
146.7  
            
4.2  
3 FEMALE 36 5.40% R EYE 
          
72.3  
          
99.3  
        
127.2  
          
14.4   L EYE  
          
70.8  
          
98.7  
        
121.2  
          
11.8  
4 FEMALE 26 5.10% R EYE 
          
67.5  
        
101.1  
        
155.1  
          
24.3   L EYE  
          
67.2  
        
101.1  
        
151.5  
          
21.8  
5 FEMALE 45 5.00% R EYE 
          
66.3  
        
101.7  
        
130.8  
          
14.6   L EYE  
          
67.2  
        
100.8  
        
130.2  
          
14.8  
7 FEMALE 28 5.60% R EYE 
          
76.8  
        
105.6  
        
138.6  
            
7.7   L EYE  
          
72.6  
        
101.4  
        
141.3  
            
6.6  
8 FEMALE 28 5.20% R EYE 
          
67.8  
          
96.3  
        
147.6  
          
25.5   L EYE  
          
69.0  
          
95.7  
        
148.5  
          
25.5  
11A FEMALE 30 5.20% R EYE 
          
69.6  
          
96.6  
        
127.8  
          
14.7   L EYE  
          
69.0  
          
96.3  
        
128.1  
          
14.0  
11B FEMALE 30 5.20% R EYE 
          
71.4  
          
95.7  
        
124.2  
          
14.7   L EYE  
          
70.2  
          
98.7  
        
128.4  
          
14.0  
12A MALE 31 5.30% R EYE 
          
72.0  
        
102.0  
        
133.5  
          
17.1   L EYE  
          
78.0  
          
99.0  
        
136.8  
          
14.6  
12B MALE 31 5.30% R EYE 
          
76.8  
        
100.8  
        
135.6  
          
17.1   L EYE  
          
76.8  
        
102.9  
        
135.9  
          
14.6  
13 FEMALE 23 5.50% R EYE 
          
67.5  
          
92.7  
        
114.3  
          
10.1   L EYE  
          
67.2  
          
88.5  
        
114.0  
          
12.2  
16A FEMALE 27 5.40% R EYE 
          
67.2  
          
99.6  
        
128.7  
            
6.7   L EYE  
          
69.9  
        
103.5  
        
129.9  
            
9.3  
122 
 
 
 
16B FEMALE 27 5.40% R EYE 
          
67.5  
        
102.3  
        
129.0  
            
6.7   L EYE  
          
68.7  
        
101.4  
        
137.1  
            
9.3  
20A MALE 32 5.40% R EYE 
          
69.0  
        
104.4  
        
134.7  
          
16.6   L EYE  
          
78.0  
        
108.3  
        
141.0  
          
18.2  
20B MALE 32 5.40% R EYE 
          
74.1  
        
104.7  
        
140.4  
          
16.6   L EYE  
          
74.7  
        
105.0  
        
144.0  
          
18.2  
22 MALE 35 5.80% R EYE 
          
84.3  
        
109.5  
        
150.6  
            
9.0   L EYE  
          
89.1  
        
109.2  
        
149.7  
            
8.0  
23A FEMALE 33 5.60% R EYE 
          
72.3  
        
104.7  
        
138.9  
          
11.6   L EYE  
          
72.3  
        
106.8  
        
147.0  
          
13.2  
23B FEMALE 33 5.60% R EYE 
          
72.3  
        
105.9  
        
135.9  
          
11.6   L EYE  
          
71.7  
        
106.5  
        
144.3  
          
13.2  
24 FEMALE 56 5.20% R EYE 
          
73.5  
          
98.7  
        
124.5  
            
5.9   L EYE  
          
72.6  
        
100.5  
        
126.6  
            
8.5  
25A MALE 34 5.30% R EYE 
          
80.4  
        
106.8  
        
134.1  
            
7.0   L EYE  
          
77.7  
        
105.6  
        
131.4  
            
5.9  
25B MALE 34 5.30% R EYE 
          
80.4  
        
104.4  
        
133.5  
            
7.0   L EYE  
          
86.4  
        
106.2  
        
129.3  
            
5.9  
26 FEMALE 37 5.40% R EYE 
          
70.8  
        
102.9  
        
143.7  
          
14.0   L EYE  
          
72.3  
        
100.2  
        
136.2  
          
17.3  
27A MALE 36 5.40% R EYE 
          
72.6  
        
100.2  
        
129.9  
          
18.7   L EYE  
          
73.8  
        
102.0  
        
127.8  
          
12.8  
27B MALE 36 5.40% R EYE 
          
71.7  
          
98.7  
        
129.0  
          
18.7   L EYE  
          
73.2  
        
102.6  
        
126.6  
          
12.8  
28A FEMALE 34 5.20% R EYE 
          
69.6  
          
99.3  
        
129.9  
          
13.8   L EYE  
          
67.8  
          
98.4  
        
121.5  
          
14.7  
28B FEMALE 34 5.20% R EYE 
          
69.3  
          
99.0  
        
129.3  
          
13.8   L EYE  
          
67.2  
          
97.8  
        
123.6  
          
14.7  
29A FEMALE 25 5.30% R EYE 
          
73.5  
        
103.2  
        
131.4  
          
16.2   L EYE  
          
71.1  
        
104.1  
        
126.0  
            
9.9  
29B FEMALE 25 5.30% R EYE 
          
69.6  
        
103.5  
        
128.7  
          
16.2   L EYE  
          
70.8  
        
104.4  
        
124.2  
            
9.9  
31A FEMALE 25 5.50% R EYE 
          
73.5  
          
98.1  
        
125.1  
            
9.0   L EYE  
          
67.2  
          
99.3  
        
117.3  
            
9.0  
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31B FEMALE 25 5.50% R EYE 
          
75.6  
          
98.1  
        
125.4  
            
9.0   L EYE  
          
67.5  
        
100.2  
        
123.3  
            
9.0  
32 MALE 38 5.40% R EYE 
          
76.2  
        
104.1  
        
134.1  
          
20.1   L EYE  
          
71.1  
        
105.0  
        
139.8  
          
20.7  
35 FEMALE 32 5.50% R EYE 
          
68.1  
          
98.7  
        
128.7  
          
12.0   L EYE  
          
69.9  
          
95.7  
        
121.2  
          
10.2  
36A MALE 57 5.50% R EYE 
          
81.0  
        
105.0  
        
139.2  
            
6.7   L EYE  
          
81.0  
        
104.1  
        
129.6  
            
6.1  
36B MALE 57 5.50% R EYE 
          
81.9  
        
106.2  
        
142.2  
            
6.7   L EYE  
          
82.5  
        
101.1  
        
134.1  
            
6.1  
48A MALE 19 5.40% R EYE 
          
71.1  
        
100.2  
        
138.0  
          
16.8   L EYE  
          
70.8  
        
103.2  
        
140.4  
          
17.8  
48B MALE 19 5.40% R EYE 
          
70.5  
        
101.1  
        
138.6  
          
16.8   L EYE  
          
71.7  
        
103.2  
        
140.4  
          
17.8  
50 FEMALE 28 5.20% R EYE 
          
76.2  
        
106.2  
        
137.7  
            
8.9   L EYE  
          
70.5  
          
99.3  
        
136.5  
            
7.6  
53A FEMALE 28 5.30% R EYE 
          
63.9  
          
96.3  
        
117.6  
          
12.2   L EYE  
          
68.4  
          
96.3  
        
121.8  
          
10.4  
53B FEMALE 28 5.30% R EYE 
          
67.8  
          
94.8  
        
115.5  
          
12.2   L EYE  
          
65.4  
          
97.5  
        
120.0  
          
10.4  
54A FEMALE 26 5.40% R EYE 
          
75.0  
        
103.2  
        
139.8  
            
6.9   L EYE  
          
69.3  
        
105.3  
        
144.3  
            
7.3  
54B FEMALE 26 5.40% R EYE 
          
72.6  
        
103.8  
        
137.4  
            
6.9   L EYE  
          
67.5  
        
103.5  
        
143.7  
            
7.3  
55A FEMALE 34 5.30% R EYE 
          
70.5  
          
97.8  
        
129.3  
            
6.4   L EYE  
          
73.5  
          
99.9  
        
123.6  
            
8.4  
55B FEMALE 34 5.30% R EYE 
          
68.4  
          
97.2  
        
128.1  
            
6.4   L EYE  
          
70.8  
          
98.4  
        
127.2  
            
8.4  
117 FEMALE 24 5.30% R EYE 
          
74.4  
          
99.0  
        
128.1  
          
19.2   L EYE  
          
71.7  
          
98.4  
        
124.2  
          
19.5  
AVERAGE 32 5.36% R EYE 
          
72.8  
        
101.2  
        
132.8  
          
12.5   L EYE  
          
72.3  
        
101.3  
        
132.4  
          
12.0  
10 Males             
20 Females             
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Data table for diabetic participants HbA1c  10% 
 
NO 
GENDE
R AGE TYPE YRS 
HbA1c 
% R EYE 
N75 
(ms) 
P100 
(ms) 
N145 
(ms) 
AMP 
(uV) L EYE 
N75 
(ms) 
P100 
(ms) 
N145 
(ms) 
AMP 
(uV)  
6 FEMALE 27 DMT2 1 6.50% R EYE 77.4 102.6 151.6 10.8 L EYE 73.5 102.9 152.1 10.6  
10 FEMALE 47 DMT2 1 6.50% R EYE 63.9 106.2 142.2 18.8 L EYE 69.9 105.3 144.0 15.6  
14 FEMALE 62 DMT2 12 7.00% R EYE 75.3 108.0 151.8 11.7 L EYE 70.8 115.8 145.5 7.2  
15 FEMALE 44 DMT2 10 7.00% R EYE 90.0 112.5 147.3 8.7 L EYE 94.8 110.4 142.5 7.8  
33 MALE 56 DMT2 5 6.20% R EYE 82.5 103.5 126.9 6.2 L EYE 88.8 108.6 133.8 6.5  
34 MALE 52 DMT2 5 7.20% R EYE 83.1 110.4 159.9 16.1 L EYE 85.2 113.1 166.2 17.4  
37 FEMALE 53 DMT2 2 5.80% R EYE 87.0 105.3 135.9 7.8 L EYE 75.6 103.2 132.3 10.5  
38 MALE 57 DMT2 5 7.20% R EYE 98.1 119.4 142.8 10.6 L EYE 97.8 120.3 149.7 10.9  
39 FEMALE 57 DMT2 5 8.30% R EYE 63.6 99.9 132.9 22.4 L EYE 66.3 100.8 130.5 20.6  
41 FEMALE 44 DMT1 20 7.00% R EYE 80.1 109.2 154.2 2.6 L EYE 79.8 119.7 163.8 3.6  
44 MALE 55 DMT2 2 8.90% R EYE 75.9 101.7 124.8 11.8 L EYE 72.9 106.5 126.9 11.6  
47 MALE 53 DMT2 6 8.00% R EYE 72.0 109.8 140.7 7.6 L EYE 74.4 114.6 155.4 8.2  
49 FEMALE 53 DMT2 24 8.20% R EYE 72.0 103.5 123.9 10.2 L EYE 78.9 99.9 122.1 7.7  
52 MALE 42 DMT2 1 7.10% R EYE 74.7 105.0 123.6 5.9 L EYE 75.0 108.0 156.3 7.9  
59 MALE 54 DMT2 6 8.60% R EYE 78.0 131.1 166.8 5.9 L EYE 72.3 124.8 166.2 6.8  
60 MALE 62 DMT2 10 6.80% R EYE 64.5 109.8 156.6 13.1 L EYE 60.6 109.2 156.3 11.7  
61 MALE 58 DMT2 7 7.20% R EYE 84.9 118.2 149.1 4.8 L EYE 89.7 119.7 152.1 6.5  
62 MALE 68 DMT2 12 7.30% R EYE 81.6 118.2 147.0 11.1 L EYE 75.6 115.6 155.4 12.5  
63 FEMALE 58 DMT2 18 6.80% R EYE 75.6 109.5 152.1 14.0 L EYE 77.1 109.5 151.5 12.4  
65 FEMALE 62 DMT2 10 6.20% R EYE 65.7 102.3 121.2 19.4 L EYE 69.9 102.0 124.5 17.9  
66 MALE 50 DMT2 1 5.50% R EYE 72.3 99.6 124.2 12.2 L EYE 71.7 103.8 126.9 9.9  
68 MALE 63 DMT2 2 6.80% R EYE 67.8 111.3 149.1 4.7 L EYE 69.0 112.2 150.3 3.2  
69 MALE 65 DMT2 1 7.40% R EYE 72.9 111.6 151.8 7.8 L EYE 79.5 119.7 152.7 7.7  
125 
 
 
 
73 FEMALE 77 DMT2 16 7.00% R EYE 86.1 110.1 164.1 8.2 L EYE 89.1 111.3 153.9 7.0  
74 MALE 46 DMT2 4 6.70% R EYE 87.6 115.3 144.0 6.5 L EYE 91.5 114.9 150.0 4.2  
76 MALE 19 DMT1 12 6.80% R EYE 71.4 106.2 140.7 14.0 L EYE 75.9 107.4 132.9 10.4  
77 FEMALE 76 DMT2 4 7.00% R EYE 72.9 111.3 145.8 13.2 L EYE 78.0 113.1 148.2 18.2  
78 MALE 76 DMT2 16 6.40% R EYE 77.1 100.2 123.9 4.4 L EYE 78.3 102.0 130.2 3.4  
79 MALE 76 DMT2 4 6.90% R EYE 46.8 106.5 149.4 26.7 L EYE 63.9 107.7 145.2 22.0  
80 MALE 25 DMT1 23 8.00% R EYE 77.1 104.7 124.5 2.9 L EYE 75.9 105.0 120.6 4.1  
81 FEMALE 66 DMT2 20 7.00% R EYE 74.1 105.0 137.4 13.1 L EYE 69.0 105.0 146.7 12.6  
82 MALE 56 DMT2 5 7.00% R EYE 69.9 104.1 126.9 9.7 L EYE 71.4 104.4 127.5 9.9  
84 MALE 55 DMT2 2 9.00% R EYE 74.1 111.3 135.3 6.7 L EYE 75.0 108.9 135.0 5.6  
85 MALE 66 DMT2 10 8.50% R EYE 78.9 108.6 139.8 15.6 L EYE 86.1 110.7 135.9 9.3  
87 FEMALE 27 DMT2 6 6.50% R EYE 70.2 101.1 128.7 13.6 L EYE 71.4 101.4 128.7 10.1  
89 MALE 66 DMT2 7 7.50% R EYE 80.7 117.3 150.0 6.1 L EYE 88.8 117.3 150.0 8.6  
92 FEMALE 67 DMT2 8 7.00% R EYE 67.5 112.8 145.5 16.2 L EYE 69.9 112.2 145.5 12.6  
93 MALE 54 DMT2 7 7.00% R EYE 69.3 108.3 144.0 5.3 L EYE 66.9 108.3 145.2 6.4  
94 MALE 64 DMT2 12 6.00% R EYE 72.6 109.5 135.6 8.9 L EYE 68.4 109.8 147.3 9.8  
95 FEMALE 61 DMT2 7 6.70% R EYE 68.4 100.8 129.9 16.6 L EYE 73.2 100.5 131.1 17.3  
96 FEMALE 58 DMT2 15 8.00% R EYE 73.8 108.3 142.5 8.6 L EYE 76.8 108.6 142.2 7.8  
97 MALE 71 DMT2 7 7.30% R EYE 69.9 118.8 154.8 10.3 L EYE 70.2 116.1 151.8 10.2  
98 MALE 34 DMT2 2 8.10% R EYE 75.3 109.8 136.2 3.5 L EYE 75.6 109.2 134.7 3.1  
10
0 MALE 59 DMT2 8 7.00% R EYE 71.7 112.5 143.1 4.7 L EYE 73.2 113.1 139.5 5.0  
10
4 MALE 51 DMT2 6 7.90% R EYE 83.7 111.3 145.2 4.3 L EYE 87.0 111.9 145.2 4.1  
10
7 MALE 67 DMT2 14 6.90% R EYE 67.5 115.5 143.4 9.8 L EYE 76.5 115.2 143.1 10.7  
11
0 FEMALE 65 DMT2 2 6.00% R EYE 69.3 105.0 137.4 13.9 L EYE 72.0 105.6 138.6 13.3  
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12
3 MALE 67 DMT2 6 7.40% R EYE 72.3 118.2 150.0 8.8 L EYE 74.7 116.1 151.8 9.3  
12
8 MALE 54 DMT2 7 7.20% R EYE 69.9 115.8 158.1 9.5 L EYE 74.7 116.4 156.6 9.6  
13
3 FEMALE 66 DMT2 5 6.70% R EYE 71.1 113.4 149.7 12.4 L EYE 70.5 113.4 148.8 12.9  
14
0 MALE 63 DMT2 5 8.20% R EYE 82.2 120.6 152.1 9.4 L EYE 87.0 120.3 146.4 10.4  
14
1 MALE 44 DMT2 1 8.20% R EYE 72.6 105.0 137.1 11.1 L EYE 68.4 105.3 136.2 10.8  
AVERAGE 
≤10% 56.1   7.8 7.18% R EYE 74.7 109.5 142.1 10.3 L EYE 76.3 110.3 143.6 9.9  
 
HbA1c ≤10% 
DMT2 - 49 Participants 
DMT1 - 3 Participants 
Males - 33 Participants 
Females - 19 Participants 
DMT1 - 2 Males 
             - 1 Female 
DMT2 - 31 Males 
             - 18 Females 
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Data table for diabetic participants HbA1c > 10% 
 
NO GENDER AGE TYPE YRS 
HbA1c 
% R EYE 
N75 
(ms) 
P100 
(ms) 
N145 
(ms) 
AMP 
(uV) L EYE 
N75 
(ms) 
P100 
(ms) 
N145 
(ms) 
AMP 
(uV)  
17 FEMALE 53 DMT2 6 10.60% R EYE 66.0 98.4 127.5 8.4 L EYE 66.0 99.9 125.7 8.1  
35 MALE 55 DMT2 2 10.60% R EYE 75.3 104.1 134.7 3.0 L EYE 67.2 98.7 120.9 3.8  
40 MALE 63 DMT2 6 10.10% R EYE 85.2 111.6 135.6 5.4 L EYE 90.0 114.3 147.3 9.1  
42 MALE 46 DMT2 3 10.50% R EYE 95.4 122.4 155.7 3.1 L EYE 99.3 122.7 149.1 3.6  
45 FEMALE 53 DMT2 7 10.10% R EYE 81.0 109.2 124.2 7.2 L EYE 70.8 105.3 129.9 3.8  
51 MALE 34 DMT1 15 11.00% R EYE 79.5 111.0 154.2 18.3 L EYE 88.2 116.7 153.9 11.5  
70 FEMALE 43 DMT1 25 10.10% R EYE 66.3 97.2 147.9 10.9 L EYE 61.5 98.4 148.2 13.0  
71 MALE 47 DMT2 3 11.00% R EYE 76.2 102.0 125.7 7.8 L EYE 73.8 101.0 123.0 5.6  
75 MALE 21 DMT1 10 13.30% R EYE 85.2 110.4 141.5 8.7 L EYE 85.8 112.5 133.2 4.5  
86 MALE 43 DMT2 1 11.00% R EYE 69.9 104.4 141.0 10.5 L EYE 73.8 105.0 153.6 10.4  
88 MALE 46 DMT2 14 10.10% R EYE 81.3 108.3 138.6 14.4 L EYE 86.4 111.0 146.7 11.3  
91 FEMALE 43 DMT2 7 13.0% R EYE 63.3 96.9 144.6 10.5 L EYE 49.5 98.7 144.9 13.6  
99 FEMALE 74 DMT2 15 11.50% R EYE 79.8 118.2 151.8 12.2 L EYE 80.7 117.9 158.7 12.4  
101 FEMALE 20 DMT1 7 15.70% R EYE 74.4 104.4 150.0 24.4 L EYE 74.4 103.8 150.0 20.9  
102 MALE 20 DMT2 1 16.90% R EYE 75.3 117.0 142.2 4.6 L EYE 71.1 117.9 152.7 5.4  
103 FEMALE 34 DMT1 13 13.60% R EYE 67.8 121.8 170.1 6.4 L EYE 66.3 121.2 172.2 5.0  
105 FEMALE 42 DMT2 2 11.00% R EYE 70.5 115.2 162.6 12.0 L EYE 78.3 115.8 164.1 12.3  
106 MALE 56 DMT2 3 11.10% R EYE 70.2 114.6 145.5 7.6 L EYE 75.0 115.2 148.8 6.9  
108 FEMALE 25 DMT2 12 10.50% R EYE 73.8 112.5 154.5 12.4 L EYE 73.5 112.5 162.3 10.4  
109 FEMALE 29 DMT1 12 10.10% R EYE 62.1 108.0 149.1 19.8 L EYE 59.1 108.0 151.5 18.5  
111 MALE 59 DMT2 15 11.60% R EYE 73.2 117.6 158.4 2.0 L EYE 73.5 118.2 153.3 4.0  
112 FEMALE 45 DMT2 1 10.10% R EYE 65.4 98.1 129.9 20.0 L EYE 66.3 97.8 132.0 22.8  
113 MALE 58 DMT2 10 10.10% R EYE 74.4 104.7 132.3 7.2 L EYE 77.7 105.3 136.8 9.0  
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114 FEMALE 50 DMT2 10 12.30% R EYE 65.7 120.2 152.8 4.6 L EYE 66.5 119.5 148.5 5.1  
115 MALE 48 DMT1 8 14.10% R EYE 72.3 109.5 146.4 15.3 L EYE 72.6 109.2 135.6 12.3  
116 FEMALE 32 DMT1 22 11.40% R EYE 70.2 117.9 165.6 3.4 L EYE 68.7 118.2 167.7 4.3  
118 FEMALE 48 DMT1 15 11.40% R EYE 63.6 97.8 120.0 10.9 L EYE 67.8 97.8 126.9 10.0  
119 MALE 61 DMT2 6 12.00% R EYE 74.4 105.0 134.4 12.0 L EYE 75.6 105.6 133.8 9.1  
120 FEMALE 33 DMT1 12 10.20% R EYE 74.1 102.6 139.5 15.2 L EYE 71.1 102.3 140.7 12.7  
121 MALE 59 DMT2 15 11.00% R EYE 73.8 116.4 147.0 3.9 L EYE 75.3 115.8 142.2 3.2  
122 MALE 40 DMT2 6 11.10% R EYE 74.4 105.9 136.8 12.4 L EYE 74.1 106.2 132.9 10.9  
124 FEMALE 51 DMT2 14 10.20% R EYE 76.5 104.7 134.4 9.2 L EYE 76.2 104.4 131.7 11.1  
125 MALE 45 DMT2 8 12.30% R EYE 79.5 115.8 145.5 1.9 L EYE 79.8 115.2 143.7 4.3  
126 MALE 43 DMT2 9 13.60% R EYE 72.0 105.6 134.1 8.7 L EYE 74.1 106.2 143.4 7.2  
127 MALE 41 DMT2 7 12.00% R EYE 75.9 109.8 149.7 9.1 L EYE 73.8 109.2 156.3 7.6  
129 MALE 54 DMT1 1.5 10.20% R EYE 75.0 111.9 138.3 5.2 L EYE 78.9 111.3 138.0 3.0  
130 MALE 53 DMT2 20 10.10% R EYE 67.8 111.6 141.3 14.4 L EYE 77.4 111.0 142.8 10.3  
131 MALE 48 DMT2 20 10.50% R EYE 56.7 111.6 140.7 6.1 L EYE 78.0 111.0 134.7 4.8  
132 MALE 49 DMT2 1 11.70% R EYE 71.1 99.9 132.0 13.2 L EYE 70.8 99.0 129.9 13.7  
134 MALE 64 DMT1 7 10.70% R EYE 63.0 105.3 136.2 13.2 L EYE 67.5 105.6 141.0 11.2  
135 MALE 51 DMT1 12 10.60% R EYE 75.0 106.5 134.4 5.6 L EYE 80.1 108.0 145.2 6.0  
136 FEMALE 67 DMT2 20 10.30% R EYE 62.7 105.0 134.1 11.7 L EYE 48.0 104.7 135.0 16.7  
137 FEMALE 18 DMT1 6 13.30% R EYE 65.7 124.2 179.4 9.0 L EYE 68.1 124.8 180.9 6.7  
138 MALE 44 DMT1 1 10.10% R EYE 61.5 106.2 141.0 17.4 L EYE 60.0 105.9 139.5 16.6  
139 FEMALE 45 DMT2 20 10.10% R EYE 65.4 104.4 136.5 8.0 L EYE 68.7 105.3 136.2 9.8  
142 MALE 64 DMT2 8 12.70% R EYE 101.4 134.1 165.9 3.9 L EYE 97.2 133.8 163.5 2.6  
143 FEMALE 36 DMT2 1 10.30% R EYE 69.9 91.5 111.9 15.7 L EYE 67.8 91.2 113.4 18.1  
144 FEMALE 28 DMT1 1 14.00% R EYE 66.0 102.6 142.5 8.1 L EYE 75.0 103.2 139.5 7.4  
145 MALE 35 DMT1 16 10.50% R EYE 75.6 109.8 153.9 13.6 L EYE 69.9 110.1 152.1 12.6  
146 FEMALE 41 DMT2 10 13.00% R EYE 70.2 100.8 125.1 17.0 L EYE 71.4 101.1 122.7 14.4  
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147 MALE 43 DMT2 2 10.50% R EYE 67.2 116.1 149.7 7.8 L EYE 68.1 116.4 150.0 10.8  
148 FEMALE 52 DMT2 5 11.00% R EYE 69.6 104.1 131.1 7.2 L EYE 71.1 103.8 132.8 9.4  
                 
AVERAGE 
>10% 
45.
2   9.1 11.44% R EYE 
          
72.5  
        
108.9  
        
142.7  
          
10.0  L EYE 
          
73.1  
        
109.1  
        
143.5  
            
9.6   
                 
HbA1c >10% 
DMT2 - 35 Participants 
DMT1 - 17 Participants 
Males - 29 Participants 
Females - 23 Participants 
DMT1 - 8 Males 
             - 9 Females 
DMT2 - 21 Males 
             - 14 Females 
 
 
 
 
 
